BSE Healthcare

INDOCO REMEDIES: CO RECEIVED 7 OBSERVATIONS IN FORM 483 ON CONCLUSION OF THE INSPECTION BY USFDA AT GOA FACILITY

THEMIS MEDICARE: CO PROJECTS 35% CAGR OVER NEXT 3 YEARS WHILE MAINTAINING EBITDA ABOVE 25% - INVESTOR PRESENTATION

THEMIS MEDICARE: CO SAYS TRANSFER OF THE API BUSINESS TO UNIT IS UNDERWAY -- CO SAYS WILL FURTHER HELP STREAMLINE OPERATIONS, THEREBY FACILITATING BETTER STRATEGY IMPLEMENTATION FOR FUTURE GROWTH IN BOTH BUSINESSES - INVESTOR PRESENTATION

THEMIS MEDICARE: CO EXPANDS TRADE BUSINESS WITH RAPID GROWTH IN PHARMA SEGMENT AND UPCOMING GENERIC LAUNCHES - INVESTOR PRESENTATION

STRIDES PHARMA: CO SAYS STRIDES NEW ZEALAND SHALL HOLD MARKET AUTHORIZATIONS FOR THE PRODUCTS IN NEW ZEALAND AND SHALL ALSO UNDERTAKE TRADING IN PHARMACEUTICAL PRODUCTS

STRIDES PHARMA: CO HAS INCORPORATED CO IN NEW ZEALAND IN THE NAME OF STRIDES PHARMA NEW ZEALAND PTY LTD

GLENMARK LIFE SCIENCES: CO SAYS GUJARAT POLLUTION CONTROL BOARD (GPCB) ISSUES CLOSURE NOTICE FOR CO’S ANKLESHWAR FACILITY

AARTI DRUGS: CO SAYS THE GUJARAT SAYAKHA GREENFIELD PROJECT FOR SPECIALTY CHEMICALS IS ON TRACK TO BEGIN BY THE END OF Q2 FY25, WITH THIS OPERATING LEVERAGE EXPECTED TO ENHANCE CAPACITY UTILIZATION FROM THE SECOND HALF OF THE YEAR - INVESTOR PRESENTATION

AARTI DRUGS: CO SAYS IN FY25, ANTICIPATE IMPROVEMENT IN MARGINS DRIVEN BY GROWTH IN EXPORT SALES -- CO SAYS ANTICIPATE TOTAL CAPEX OF 2B RUPEES FOR FY25

THEMIS MEDICARE: Q1 EBITDA 292M RUPEES VS 114M (YOY) -- Q1 EBITDA MARGIN 27.56% VS 16.50% (YOY)

THEMIS MEDICARE: Q1 REVENUE 1.06B RUPEES VS 693M (YOY)

THEMIS MEDICARE: Q1 SL NET PROFIT FROM CONTINUING OPERATION 203M RUPEES VS 68M (YOY); 42M (QOQ)

AARTI DRUGS: Q1 EBITDA 650M RUPEES VS 841M (YOY) -- Q1 EBITDA MARGIN 11.70% VS 12.72% (YOY)

AARTI DRUGS: Q1 REVENUE 5.6B RUPEES VS 6.61B (YOY)

AARTI DRUGS: Q1 CONS NET PROFIT 332M RUPEES VS 478M (YOY); 474M (QOQ)

CIPLA: COS SOUTH AFRICA: MOMENTUM CONTINUES WITH REVENUE GROWTH AT 19% IN LOCAL CURRENCY TERMS -- CO SAYS PRESCRIPTION BUSINESS RANKED 1 IN THE MARKET

CIPLA: COS NORTH AMERICA: ALL-TIME HIGH REVENUE AT USD 250M UP BY 13% YOY SUPPORTED BY TRACTION IN DIFFERENTIATED PORTFOLIO

CIPLA: Q1 EBITDA 17.2B RUPEES VS 14.94B (YOY); EST 16.13B -- Q1 EBITDA MARGIN 25.63% VS 23.60% (YOY); EST 23.8%

CIPLA: Q1 REVENUE 67B RUPEES VS 63.28B (YOY); EST 67.74B

CIPLA: Q1 CONS NET PROFIT 11.8B RUPEES VS 9.95B (YOY); EST 10.87B

ALEMBIC PHARMA: CO SAYS GMP INSPECTION AT PANELAV FACILITY WAS SUCCESSFULLY COMPLETED WITHOUT ANY FORM 483 OBSERVATION

PIRAMAL PHARMA: CO CHAIRPERSON SAYS IN CHG BUSINESS, PLANNED EXPANSION FOR INHALATION ANESTHESIA PORTFOLIO IS ON TRACK AND IS EXPECTED TO GET COMMERCIALIZED IN FY26

PIRAMAL PHARMA: Q1 EBITDA 2.24B RUPEES VS 1.71B (YOY) -- Q1 EBITDA MARGIN 11% VS 10% (YOY) (AS PER CO STATEMENT)

PIRAMAL PHARMA: Q1 CONS NET LOSS 886M RUPEES VS LOSS 986M (YOY) -- Q1 REVENUE 19B RUPEES VS 17.5B (YOY)

PIRAMAL PHARMA: Q1 EBITDA 1.51B RUPEES VS 165M (YOY) -- Q1 EBITDA MARGIN 14.26% VS 1.96% (YOY)

PIRAMAL PHARMA: Q1 REVENUE 10.6B RUPEES VS 8.46B (YOY)

PIRAMAL PHARMA: Q1 SL NET PROFIT 850M RUPEES VS LOSS 333.6M (YOY)

MANKIND PHARMA LTD: RS. 62.55 CRORES NSE BLOCK TRADE; FOR ~ 301966 SHARES, AT RS. 2071.30

LAURUS LABS: CO EXPECTS FY 25 TO BE A GOOD YEAR, WITH FY 26 EXPECTED TO BE EVEN BETTER DUE TO INVESTMENTS IN AREAS LIKE ANIMAL HEALTH STARTING TO YIELD RESULTS - CONCALL UPDATE

LAURUS LABS: CO EXPECTS AN IMPROVEMENT IN EBITDA IN THE SECOND HALF OF THE YEAR -- CO IS TARGETING A NET DEBT TO EBITDA RATIO OF LESS THAN 2.5X BY THE END OF MARCH 25 - CONCALL UPDATE

LAURUS LABS: CO REMAINS COMMITTED TO A HEALTHY GROWTH OUTLOOK FOR THE FULL YEAR, SUPPORTED BY SCHEDULED PROJECT DELIVERIES FOR KEY LATE-PHASE NCE PROJECTS IN Q4 OF THIS FINANCIAL YEAR - CONCALL UPDATE

SUN PHARMA: COS LEQSELVI (DEURUXOLITINIB) RECEIVES U.S. FDA APPROVAL FOR SEVERE ALOPECIA AREATA; ACHIEVES SIGNIFICANT EFFICACY IN PHASE 3 TRIALS

MANKIND PHARMA: CO TO ACQUIRE 100% STAKE IN BHARAT SERUMS AND VACCINES (BSV), FOR AN ENTERPRISE VALUE OF APPROX 136.3B RUPEES -- CO EXPANDS HIGH ENTRY BARRIER PORTFOLIO; LEADERSHIP IN WOMEN’S HEALTH

GLENMARK LIFE: CO ANTICIPATE DELIVERING STEADY GROWTH WITH STABLE MARGINS THROUGHOUT FY25 - INVESTOR PRESENTATION

GLENMARK LIFE: CO SAYS ANKLESHWAR CAPACITY EXPANSION CONSTRUCTION COMPLETED, TO BE OPERATIONAL IN Q2FY25

GLENMARK LIFE: CO SAYS ANTICIPATE DELIVERING STEADY GROWTH WITH STABLE MARGINS THROUGHOUT FY25 -- OPTIMISTIC ABOUT MAINTAINING GROWTH MOMENTUM FOR REST OF YEAR

GLENMARK LIFE SCIENCES: Q1 EBITDA 1.6B RUPEES VS 1.9B (YOY) -- Q1 EBITDA MARGIN 27.10% VS 33.38% (YOY)

GLENMARK LIFE SCIENCES: Q1 REVENUE 5.9B RUPEES VS 5.8B (YOY)

GLENMARK LIFE SCIENCES: Q1 SL NET PROFIT 1.1B RUPEES VS 1.35B (YOY); 979M (QOQ)

LAURUS LABS: CO CFO SAYS WE REMAIN COMMITTED TO FY2025 OUTLOOK AND OUR KEY CAPEX PROJECTS INTO HIGH VALUE BUSINESS SEGMENTS IS ADVANCING WELL TO DRIVE MEDIUM AND LONG TERM GROWTH

LAURUS LABS: CO CFO SAYS WE EXPECT PERFORMANCE TO PICK UP MOSTLY FROM H2, SUPPORTED BY ON HAND PROJECT DELIVERIES

LAURUS LABS: Q1 EBITDA 1.71B RUPEES VS 1.67B (YOY); EST 2.54B -- Q1 EBITDA ARGIN 14.33% VS 14.11% (YOY); EST 17.5%

LAURUS LABS: Q1 REVENUE 11.9B RUPEES VS 11.8B (YOY); EST 14.59B

LAURUS LABS: Q1 CONS NET PROFIT 125M RUPEES VS 248M (YOY); EST 913M

GLENMARK LIFE: ISSUE OF CLOSURE NOTICE FOR OUR ANKLESHWAR FACILITY BY GPCB -- GPCB ORDERED NOT TO CARRY PRODUCTION AT ANKLESHWAR FACILITY

GLAND PHARMA: CO SAYS INSPECTION WAS CONCLUDED WITH TWO (2) 483 OBSERVATIONS AT CO’S DUNDIGAL FACILITY

JAGSONPAL PHARMA: CO SIGNS AGREEMENT TO SELL NON-OPERATIONAL FARIDABAD FACILITY FOR RS. 41 CR

POLY MEDICURE: CO IS MANUFACTURING A PRODUCT IN INDIA AND WILL BE TRAINING THE SALES TEAM ON THE PRODUCT LINE INITIALLY, BUT THE BUSINESS WILL BE MANAGED LOCALLY BY THE PARTNER - CONCALL UPDATE

POLY MEDICURE: CO PLANS TO DEPLOY PART OF ITS FUNDS INTO INORGANIC OPPORTUNITIES TO ENHANCE TECHNOLOGY AND SHORTEN THE PRODUCT DEVELOPMENT CYCLE - CONCALL UPDATE

POLY MEDICURE: CO WILL USE AI-BASED TOOLS TO CONDUCT TRAINING PROGRAMS FOR INTERNATIONAL CLIENTS, NURSES, AND DOCTOR - CONCALL UPDATE

POLY MEDICURE: CO CONTINUES TO GUIDE 22% TO 24% REVENUE GROWTH FOR FY 25 AND 100-200 BPS MARGIN IMPROVEMENT OVER THIS CURRENT FINANCIAL YEAR - CONCALL UPDATE

POLY MEDICURE: CO IS ON TRACK TO PERFORM THIS YEAR AS PER THE GUIDANCE GIVEN EARLIER OF 22% TO 24% GROWTH, AND ALSO IMPROVEMENT IN THE EBITDA MARGIN OF 250 BPS - CONCALL UPDATE

SUN PHARMA: CO SAYS ADDITIONAL INFORMATION ON DADRA FACILITY RECEIVES WARNING LETTER FROM USFDA -- CO SAYS THERE IS NO IMPACT ON COS FINANCIAL, OPERATIONS, OR OTHER ACTIVITIES

SYNGENE INTERNATIONAL: CO MD SAYS BASED ON THE CURRENT DYNAMICS, WE ARE ON TRACK TO HIT OUR GUIDANCE RANGE FOR THE YEAR WITH MOMENTUM EXPECTED TO BUILD IN THE SECOND HALF OF THE YEAR

SYNGENE INTERNATIONAL: Q1 PROFIT BEFORE TAX AND EXCEPDONAL ITEMS 693M RS VS 1.23B (YOY) -- CO HAS AN EXCEPTIONAL ITEM OF 320M RS

SYNGENE INTERNATIONAL: Q1 EBITDA 1.69B RUPEES VS 2.11B (YOY) -- Q1 EBITDA MARGIN 21.50% VS 26.22% (YOY)

SYNGENE INTERNATIONAL: Q1 REVENUE 7.9B RUPEES VS 7.16B (YOY)

SYNGENE INTERNATIONAL: Q1 CONS NET PROFIT 757M RUPEES VS 934M (YOY)

BLISS GVS PHARMA: Q1 EBITDA 343M RUPEES VS 242M (YOY) -- Q1 EBITDA MARGIN 18.69% VS 15.18% (YOY)

BLISS GVS PHARMA: Q1 REVENUE 1.8B RUPEES VS 1.59B (YOY)

BLISS GVS PHARMA: Q1 CONS NET PROFIT 207M RUPEES VS 147M (YOY)

ALEMBIC PHARMACEUTICALS: CO RECEIVES USFDA FINAL APPROVAL FOR FLUPHENAZINE HYDROCHLORIDE TABLETS

IPCA LAB: CO TO CONSIDER Q1 RESULTS ON AUG 13

MANKIND PHARMA LTD: RS. 63.69 CRORES NSE BLOCK TRADE; FOR ~ 304720 SHARES, AT RS. 2090.15

TORRENT PHARMA: CO IS LOOKING TO ADD ONE MORE PRODUCT TO ITS PORTFOLIO TOWARDS THE END OF THE YEAR -- NEW PRODUCT LAUNCHES ARE EXPECTED IN THE US OVER THE NEXT TWO TO THREE YEARS, WHICH SHOULD DRIVE POSITIVELY TO THE OVERALL PERFORMANCE OF THE CO - CONCALL UPDATE

TORRENT PHARMA: CO PLANS TO LAUNCH FIVE PRODUCTS IN BRAZIL DURING THE REST OF THE YEAR AND INTENDS TO MAINTAIN THREE TO SIX LAUNCHES PER YEAR - CONCALL UPDATE

TORRENT PHARMA: CO EXPECTS 5-10 APPROVALS THIS YEAR, WHICH WOULD DRIVE SALES GROWTH -- CO EXPECTS A HIGHER RATE OF APPROVALS NEXT YEAR ONWARDS -- GUIDANCE GIVEN HOLDS TRUE, AND MARGIN IMPROVEMENT IS EXPECTED TO HAPPEN ON A FULL-YEAR BASIS - CONCALL UPDATE

KRSNAA DIAGNOSTICS: CO HAS RECEIVED THE SIGNED AGREEMENT FROM THE GOVT OF MADHYA PRADESH FOR SETTING UP, OPERATING, MANAGING & MAINTAINING OF MRI SCAN (1.5 TESLA) MACHINES AT 5 (FIVE) DISTRICT HOSPITALS OF MADHYA PRADESH NAMELY BHOPAL, INDORE, UJJAIN, GWALIOR & JABALPUR RESPECTIVELY

SUVEN PHARMA: CO GETS OBSERVATION LETTER WITH NO ADVERSE OBSERVATIONS FROM BSE AND NO OBSERVATIONS FROM NSE -- OBSERVATIONS FOR SCHEME OF AMALGAMATION SEEKING AMALGAMATION OF COHANCE LIFESCIENCES WITH CO

PIRAMAL PHARMA: CO TO ENTER INTO AGREEMENTS WITH CLEAN MAX AERO, CLEAN MAX ENVIRO ENERGY SOLUTIONS -- DEAL FOR 21.6M RUPEES

DR REDDYS LAB: BOARD MEETING ON JULY 27 TO CONSIDER SUB-DIVISION/ SPLIT OF EXISTING SHARES

KIMS: CO RECEIVED INTIMATION ABOUT THE PROPOSED MERGER OF RAJYALAKSHMI HEALTHCARE PRIVATE A STEP DOWN SUBSIDIARY OF CO WITH ITS HOLDING CO, SARVEJANA HEALTHCARE PRIVATE LIMITED, HAS BEEN APPROVED

TORRENT PHARMACEUTICALS: Q1 EBITDA 9B RUPEES VS 7.91B (YOY) -- Q1 EBITDA MARGIN 31.62% VS 30.53% (YOY)

TORRENT PHARMACEUTICALS: Q1 REVENUE 28.6B RUPEES VS 25.91B (YOY)

TORRENT PHARMACEUTICALS: Q1 CONS NET PROFIT 4.6b RUPEES VS 3.78B (YOY)

SHILPA MEDICARE: CO UNIT SHILPA PHARMA LIFESCIENCES, UNIT 2 CLEARED COFEPRIS-MEXICO GMP INSPECTION -- CO UNIT ISSUED GMP CERTIFICATION FROM COFEPRIS-MEXICO

IOL CHEMICALS AND PHARMACEUTICALS: CO SAYS THIS CERTIFICATION WILL ENABLE THE CO TO EXPORT THIS PRODUCT IN EUROPEAN AND OTHER CEP ACCEPTING COUNTRIES -- VALSARTAN IS USED FOR TO TREAT HIGH BLOOD PRESSURE (HYPERTENSION)

IOL CHEMICALS AND PHARMACEUTICALS: CO SAYS EUROPEAN DIRECTORATE FOR THE QUALITY OF MEDICINES & HEALTH CARE (EDQM) HAS ISSUED A CERTIFICATE OF SUITABILITY FOR “VALSARTAN”

THYROCARE TECHNOLOGIES: Q1 EBITDA 426.4M RUPEES VS 345M (YOY) -- Q1 EBITDA MARGIN 27.17% VS 25.58% (YOY)

THYROCARE TECHNOLOGIES: Q1 REVENUE 1.57B RUPEES VS 1.35B (YOY)

THYROCARE TECHNOLOGIES: Q1 CONS NET PROFIT 241.7M RUPEES VS 173M (YOY)

GLAND PHARMA: CO RECEIVES TENTATIVE APPROVAL FROM THE USFDA FOR LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION -- SOLUTION HAS US SALES OF APPROXIMATELY USD 153 MILLION

GLOBAL HEALTH: CO SECURES MHADA LAND PARCEL IN MUMBAI FOR RUPEES 125.11 CR

ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVAL FROM USFDA FOR VALSARTAN TABLETS

CIPLA LTD: Rs. 30.12 Crores NSE Block Trade; for ~ 201578 Shares, at Rs. 1494.00

SOLARA ACTIVE PHARMA: CO REAFFIRMED ITS GUIDANCE FOR THE FULL YEAR. REVENUE GUIDANCE IS IN THE RANGE OF RUPES 1,400 CRORES TO RUPEES 1,500 CRORES -- CO HAS PROVIDED GUIDANCE FOR EBITDA, EXPECTING TO REACH 20% TO 22%, WHICH IS ALMOST A HISTORICAL HIGH. - CONCALL UPDATE

PFIZER: BOARD MEETING ON JULY 29 TO CONSIDER Q1 RESULTS

SOLARA ACTIVE PHARMA SCIENCES: Q1 REVENUE 3.63B RUPEES VS 3.52B (YOY)

SOLARA ACTIVE PHARMA SCIENCES: Q1 EBITDA 419M RUPEES VS 200M (YOY) -- Q1 EBITDA MARGIN 11.5% VS 5.68% (YOY)

SOLARA ACTIVE PHARMA SCIENCES: CO REAFFIRMS FY25 GUIDANCE OF REVENUE ~INR 15,000 MN & THE FULL YEAR EBITDA ~INR. 2,300 TO 2,600 MN WITH Q4’25 EXIT QUARTER REVENUE ~ INR. 4,000 MN & EBITDA OF ~INR 800 TO INR 900 MN (EBITDA MARGINS OF 20-22

SOLARA ACTIVE PHARMA SCIENCES: CO SAYS OUR NET DEBT TO EBITDA GUIDANCE IS ~3 TIMES BY Q4’25. THE COMPANY IS CONFIDENT OF BEATING THE NET DEBT TO EBITDA GUIDANCE.

SOLARA ACTIVE PHARMA SCIENCES: Q1 CONS NET LOSS 135M RUPEES VS LOSS 196M (YOY)

POLY MEDICURE: Q1 REVENUE 3.85B RUPEES VS 3.2B (YOY)

POLY MEDICURE: Q1 EBITDA 1B RUPEES VS 872M (YOY) -- Q1 EBITDA MARGIN 27.54% VS 27.18% (YOY)

POLY MEDICURE: Q1 CONS NET PROFIT 740M RUPEES VS 627M (YOY)

ZYDUS LIFE: RS 124.29CR BSE BLOCK TRADE; FOR ~1075533 SHARES, AT RS 1155.65

MANKIND PHARMA LTD: Rs. 47.24 Crores NSE Block Trade; for ~ 223388 Shares, at Rs. 2114.70

ZYDUS LIFE: CO RECEIVES APPROVAL FROM COFEPRIS OF MEXICO TO MARKET  BHAVA™ (BEVACIZUMAB BIOSIMILAR) TO TREAT VARIOUS CANCERS

ASTER DM HEALTHCARE: CO UNIT MALABAR INSTITUTE OF MEDICAL SCIENCES TO ACQUIRE 25% STAKE IN USOLAR ASSETCO -- COST OF ACQUISITION 78.8M RUPEES

RPG LIFE SCIENCES: Q1 EBITDA 391M RUPEES VS 322M (YOY) -- Q1 EBITDA MARGIN 23.62% VS 21.82% (YOY)

RPG LIFE SCIENCES: Q1 REVENUE 1.65B RUPEES VS 1.48B (YOY)

RPG LIFE SCIENCES: Q1 SL NET PROFIT 268M RUPEES VS 221M (YOY)

ZYDUS LIFE: CO IS CONFIDENT OF ADDRESSING FDA ISSUES WITHIN TIMELINE

ZYDUS LIFE: CO SAYS USFDA CONDUCTED AN INSPECTION AT THE GROUP’S TRANSDERMAL MANUFACTURING SITE LOCATED AT SEZ IN AHMEDABAD -- THE INSPECTION CLOSED WITH 2 OBSERVATIONS

JUBILANT PHARMOVA: Q1 REVENUE 17.2B RUPEES VS 15.66B (YOY)

JUBILANT PHARMOVA: Q1 CONS NET PROFIT 4.8B RUPEES VS 64M (YOY) -- CO HAS ONE TIME EXCEPTIONAL GAIN OF 3.96B

JUBILANT PHARMOVA: Q1 CONS NET PROFIT BEFORE EXCEPTIONAL ITEM 1.03B RUPEES VS 266M (YOY) -- CO HAS AN EXCEPTIONAL ITEM OF 3.9B RUPEES

JUBILANT PHARMOVA: Q1 EBITDA 2.5B RUPEES VS 1.7B (YOY) -- Q1 EBITDA MARGIN 14.52% VS 10.69%(YOY)

DIVIS LAB: CO SAYS USFDA INSPECTION IS SUCEESFULLY COMPLETED WITH ONE PROCEDURAL OBSERVATION AT ANDHRA PLANT

ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVAL FROM USFDA FOR NDA ZITUVIMETTM XR (SITAGLIPTIN AND METFORMIN HYDROCHLORIDE) EXTENDED-RELEASE TABLETS -- TABLETS HAS US SALES HAS US SALES OF APPROX 9.5B USD

CAPLIN POINT LABS: CAPLIN STERILES GETS USFDA APPROVAL FOR EPHEDRINE SULFATE INJECTION USP

GLOBAL HEALTH LTD: Rs. 29.18 Crores NSE Block Trade; for ~ 242359 Shares, at Rs. 1204.15

ZYDUS LIFESCIENCES: CO GUJARAT PLANT RECEIVES OFFICIAL ACTION INDICATED NOTICE FROM USFDA

DR. REDDY’S LAB: CO SIGNS NON-EXCLUSIVE PATENT LICENSING AGREEMENT WITH TAKEDA TO COMMERCIALISE VONOPRAZAN, A NOVEL GASTROINTESTINAL DRUG, IN INDIA

CIPLA LTD: Rs. 37.91 Crores NSE Block Trade; for ~ 251497 Shares, at Rs. 1507.45

AUROBINDO PHARMA: CO FIXES JULY 30, 2024 AS RECORD DATE FOR SHARE BUYBACK

AUROBINDO PHARMA: CO APPROVED SHARE BUYBACK AT THE PRICE OF RUPEES 1460 VIA TENDER OFFER ROUTE

VIMTA LABS: CO TARGETS RUPEES 500 CR REVENUE BY FY26: NEW LIFESCIENCES CAPACITY TO DRIVE FUTURE GROWTH -- SLIGHT QOQ IMPROVEMENT WITH 30.6% OPM - INVESTOR PRESENTATION

VIMTA LABS: Q1 EBITDA 245.2M RUPEES VS 247M (YOY) -- Q1 EBITDA MARGIN 29.99% VS 29.53% (YOY)

VIMTA LABS: Q1 REVENUE 817.6M RUPEES VS 835M (YOY)

VIMTA LABS: Q1 CONS NET PROFIT 122.8M RUPEES VS 122M (YOY)

AARTI DRUGS: CO SAYS RECEIVED AN ORDER FROM MAHARASHTRA POLLUTION CONTROL BOARD (MPCB) ISSUING VOLUNTARY CLOSURE DIRECTIONS OF MANUFACTURING ACTIVITY OF PARTICULAR PRODUCT AT T-150 UNIT LOCATED AT TARAPUR, MAHARASHTRA

ZYDUS LIFESCIENCES: ZYDUS ANNOUNCES NON-EXCLUSIVE PATENT LICENSING AGREEMENT WITH TAKEDA FOR ‘VAULT® ’ (VONOPRAZAN) IN INDIA -- VONOPRAZAN IS A NOVEL GASTROINTESTINAL DRUG AND IS A NEXT GENERATION TREATMENT FOR GASTRO DUODENAL ULCER AND GERD

GLOBAL HEALTH: CO SAYS PARTICIPATED IN E-AUCTION TENDER OF LAND ISSUED BY MUMBAI HOUSING AUTHORITY -- OFFERED 1.25B RUPEES FOR LAND

GLENMARK PHARMACEUTICALS: CO RECEIVES ANDA APPROVAL FOR TOPIRAMATE CAPSULES USP, 15 MG AND 25 MG -- ACCORDING TO IQVIA SALES DATA FOR THE 12-MONTH PERIOD ENDING MAY 2024, THE TOPAMAX® CAPSULES, 15 MG AND 25 MG MARKET3 ACHIEVED ANNUAL SALES OF APPROXIMATELY $21.9M

CIPLA: CO DISCLOSES ADDITIONAL TAX DEMAND OF RS 773.44 CRORE

ASTER DM HEALTHCARE: CO SAYS GOT COMPLAINTS ON ALLEGED UNETHICAL PRACTICES BY SOME EMPLOYEES ; CO TO INITIATE FORENSIC PROBE ON ALLEGED UNETHICAL PRACTICES -- CO SAYS GRANT THORNTON BHARAT TO INITIATE FORENSIC PROBE; ALLEGATIONS PERTAIN TO ASTER HOSPITALS LOCATED IN MEDCITY, KANNUR AND CALICUT

UNICHEM LAB: CO WILL PROVIDE THE NECESSARY RESPONSE WITH IN STIPULATED 15 WORKING DAYS

UNICHEM LAB: CO SAYS AT GOA PLANT THE USFDA INSPECTION CLOSED WITH FIVE OBSERVATIONS WHICH WERE MORE OF PROCEDURAL CHANGES WITH NONE OF THESE RELATED TO DATA INTEGRITY

SUN PHARMA: BOARD MEETING ON AUG 1 TO CONSIDER Q1 RESULTS

LUPIN: CO DIVESTS U.S. COMMERCIAL WOMEN’S HEALTH SPECIALTY BUSINESS TO EVOFEM, INCLUDING SOLOSEC -- TOTAL CONSIDERATION OF UP TO USD 84M

GRANULES INDIA: CO TO CONSIDER Q1 RESULTS ON JULY 30

CIPLA LTD: RS. 62.28 CRORES NSE BLOCK TRADE; FOR ~ 408027 SHARES, AT RS. 1526.25

NARAYANA HRUDAYALAYA LTD: RS. 116.80 CRORES NSE BLOCK TRADE; FOR ~ 960535 SHARES, AT RS. 1216.00

DIVIS LABORATORIES LTD: Rs. 47.64 Crores NSE Block Trade; for ~ 104435 Shares, at Rs. 4562.05

ERIS LIFESCIENCES LTD: RS. 201.02 CRORES NSE BLOCK TRADE; FOR ~ 2001913 SHARES, AT RS. 1004.15

LUPIN: CO GETS USFDA NOD FOR GENERIC MEDICATION-- CO HAS RECEIVED APPROVAL FROM THE USFDA TO MARKET TOPIRAMATE EXTENDED-RELEASE CAPSULES IN THE US, THE DRUG FIRM SAID IN A STATEMENT

ALEMBIC PHARMA: CO RECEIVED ANDA APPROVAL FOR BLOOD-PRESSURE DRUG

PIRAMAL PHARMA: CO SAYS THE INSPECTION AT PPDS AHMEDABAD FACILITY WAS COMPLETED SUCCESSFULLY WITH ZERO FORM - 483 OBSERVATIONS AND NO ACTION INDICATED (NAI) DESIGNATION

ALEMBIC PHARMACEUTICALS: CO ANNOUNCES USFDA TENTATIVE APPROVAL FOR SELEXIPAG FOR INJECTION, 1,800 MCG/VIAL

LUPIN: CO RECEIVES EIR FROM U.S. FDA FOR ITS DABHASA FACILITY -- INSPECTION CONCLUDED WITH NO OBSERVATIONS; FACILITY RECEIVING INSPECTION CLASSIFICATION OF NO ACTION INDICATED

ALKEM LABS: Rs 29.44cr NSE Block Trade; for ~56530 shares, at Rs 5207.15

JB CHEMICALS & PHARMACEUTICALS LTD: Rs. 20.94 Crores NSE Block Trade; for ~ 121498 Shares, at Rs. 1723.40

LAURUS LABS LTD: Rs. 38.13 Crores NSE Block Trade; for ~ 810731 Shares, at Rs. 470.35

NARAYANA HRUDAYALAYA LTD: RS. 62.81 CRORES NSE BLOCK TRADE; FOR ~ 506119 SHARES, AT RS. 1240.95

BAJAJ HEALTHCARE: CO APPROVED ISSUANCE OF CONVERTIBLE EQUITY WARRANTS WORTH 70.3CR RUPEES

BAJAJ HEALTHCARE: CO APPROVED ISSUANCE OF EQUITY SHARES ON PREFERENTIAL BASIS WORTH 136.7CR RUPEES

SHALBY: CO GETS LEASE ORDER ON IMMOVEABLE PROPERTY OF TRUST ASHA PAREKH HOSPITAL FOR 30 YEARS -- CO TO EXPAND ITS HORIZON IN SANTACRUZ, MUMBAI BY CONSTRUCTING NEW HEALTHCARE FACILITY OF 175+ BEDDED

GLENMARK PHARMA: CO AND GLEN SALDANHA TO SELL UP TO 7.85% STAKE VIA OFS -- FLOOR PRICE FOR OFS SET AT RS 810/SHARE -- OFS TO OPEN FOR NON-RETAIL INVESTORS ON JULY 11, AND ON JULY 12 FOR RETAIL INVESTORS

GLENMARK PHARMA: CO TO SELL UP TO 7.84% STAKE OF GLENMARK LIFE SCIENCES

ZYDUS LIFE: CO RECEIVES TENTATIVE APPROVAL FROM USFDA FOR DIROXIMEL FUMARATE DELAYED-RELEASE CAPSULES -- CAPSULES HAS US SALES OF 847M USD

ZYDUS: CO RECEIVES FINAL APPROVAL FROM USFDA FOR SACUBITRIL AND VALSARTAN TABLETS -- TABLETS HAS US SALES HAS US SALES OF APPROX 5.5B USD

MANKIND PHARMA: RS 730.69CR NSE BLOCK TRADE; FOR ~3509576 SHARES, AT RS 2082 (MULTIPLE BLOCKS) (PRE-OPEN)

SHALBY: CO SAYS FUTURE CAPEX WILL BE INCURRED FOR THE CAPACITY EXPANSION OF 130 BEDS TO 200 BEDS IN THE COMING YEAR FROM THE SANAR PROSPECT - CONCALL UPDATE

SHALBY: CO EXPECTS TO REACH BREAKEVEN AT EBITDA LEVEL NEXT QUARTER ONWARDS -- CO EXPECTS TO REACH OVERALL BREAKEVEN BY THE END OF THIS FINANCIAL YEAR OR EARLY NEXT FINANCIAL QUARTER - CONCALL UPDATE

MANKIND PHARMA: BLOCK DEAL ALERT - HEMA CIPEF PLANS TO SELL 37 LAC SHARES VIA BLOCK DEAL (0.9% EQUITY) -- FLOOR PRICE AT 2061 PER SHARE, 2% DISCOUNT -- DEAL LIKELY IN BLOCK WINDOW FOR RS 762 CRS -- IIFL BROKER TO DEAL - CNBC AWAAZ, CITING SOURCES

LUPIN: CO IN AUSTRALIA, ANTICIPATES MARKET EROSION IN TOP PRODUCTS DUE TO NEW ENTRANTS - ANNUAL REPORT

LUPIN: CO SAYS FY25 GROWTH IN BRAZIL TO BE DRIVEN BY PRICE HIKES, PERFORMANCE OF KEY PRODUCTS - ANNUAL REPORT

AARTI DRUGS: CO SAYS N-198 UNIT AT TARAPUR IN WHICH THE FIRE HAS OCCURRED IS OPERATIONAL AGAIN -- CO SAYS THERE HAS BEEN NO MATERIAL IMPACT ON THE FINANCIALS AND OPERATIONS OF BUSINESS

KRISHNA INSTITUTE OF MEDICAL SCIENCES: CO ANNOUNCES ACQUISITION OF 200-BED MULTI-SPECIALTY HOSPITAL AT A PRIME LOCATION IN VIZAG CURRENTLY OPERATING UNDER THE BRAND NAME OF ‘QUEENS NRI HOSPITAL’, THROUGH PURCHASE OF 100% STAKE IN M/S. CHALASANI HOSPITALS PVT LTD, OWNER OF THE HOSPITAL

SHILPA MEDICARE: CO SAYS UNIT 2, RAICHUR CLEARED ANVISA-BRAZIL GMP INSPECTION

ALEMBIC PHARMACEUTICALS: CO ANNOUNCES USFDA FINAL APPROVAL FOR BROMFENAC OPHTHALMIC SOLUTION -- SOLUTION HAS AN ESTIMATED MARKET SIZE OF 168M USD

METROPOLIS HEALTHCARE: COS B2C REVENUES GREW AT 18% YOY FOR Q1FY25

METROPOLIS HEALTHCARE: CO IS DEBT FREE & HAVING CASH RESERVES OF RUPEES 140 CRORES AS ON JUNE 30, 2024

METROPOLIS HEALTHCARE: COS REVENUES GREW BY 13% FOR Q1FY25 ON YOY BASIS

SHRIRAM AMC: CO LISTS LIQUIDSHRI ETF, BOLSTERING SHRIRAM AMC 2.0 GROWTH STRATEGY

VIJAYA DIAGNOSTIC CENTRE LTD: RS. 175.48 CRORES NSE BLOCK TRADE; FOR ~ 2241183 SHARES, AT RS. 783.00

MANKIND PHARMA LTD: Rs. 21.89 Crores NSE Block Trade; for ~ 102796 Shares, at Rs. 2129.85

DR LAL PATHLABS LTD: Rs. 15.07 Crores NSE Block Trade; for ~ 51036 Shares, at Rs. 2953.30

SUN PHARMA: CO EXPECTS HIGH SINGLE-DIGIT CONSOLIDATED TOPLINE GROWTH FOR FY25 -- CO SAYS EXPECT TO START ENROLLING PATIENTS FOR PHASE-2 TRIALS OF WEIGHT LOSS DRUG GLP-1R DURING H2CY24 - ANNUAL REPORT

SHALBY: Q1 EBITDA MARGIN 16.21% VS 18.32% (YOY)

SHALBY: Q1 REVENUE 2.8B RUPEES VS 2.35B (YOY)

SHALBY: Q1 CONS NET PROFIT 166M RUPEES VS 208M (YOY)

POLY MEDICURE LTD: RS. 95.38 CRORES NSE BLOCK TRADE; FOR ~ 452389 SHARES, AT RS. 2108.45

SHILPA MEDICARE: CO SAYS EXPECT ORDER FOR 5M TABLETS BEFORE JUNE 2025 & 15M BEFORE DEC 2025 - CNBCTV18

APOLLO HOSPITALS: CO TO ACQUIRE 35,12,107 EQUITY SHARES OF AHLL FOR RUPEES 103 CR VIA RIGHTS ISSUE, ENHANCING AHLLS BUSINESS OPERATIONS, WORKING CAPITAL, AND EXPANSION IN HEALTHCARE SERVICES

BAJAJ HEALTHCARE: BOARD MEETING ON JULY 10 TO CONSIDER RAISING OF FUNDS

TORRENT PHARMA: BOARD MEETING ON JULY 23 TO CONSIDER Q1 RESULTS

GLENMARK LIFE SCIENCES: CO SAYS RESTRICTION WAIVED TO FACILITATE COMPLIANCE WITH MINIMUM PUBLIC SHAREHOLDING REQUIREMENTS

GLENMARK LIFE SCIENCES: CO ENTERED INTO A LETTER AGREEMENT WITH GLENMARK PHARMACEUTICALS AND NIRMA; AGREEMENT AMENDS EARLIER SHARE PURCHASE AGREEMENT -- AGREEMENT HAS WAIVED CONTRACTUAL RESTRICTION IMPOSED ON SELLER; IF SELLER IS NOT ABLE TO COMPLETE SALE OF SHAREHOLDING, RESTRICTIONS SHALL BE REINSTATED

SHILPA MEDICARE: SHILPAS CDMO CUSTOMER REPORTED POSITIVE RESULTS FROM PIVOTAL CLINICAL TRIAL -- UNICYCIVE ENTERS MANUFACTURING, SUPPLY AGREEMENT WITH CO; SML EXPECTED TO GET $10M AS MILESTONE INCOME

CIPLA: CO SAYS DISSOLUTION OF WHOLLY OWNED STEP-DOWN SUBSIDIARY IN PHILIPPINES

ZYDUS LIFESCIENCES: CO RECEIVES TENTATIVE APPROVAL FROM US FDA FOR AZILSARTAN MEDOXOMIL TABLETS -- TABLETS HAS AN ANNUAL SALES OF 89M USD

SUN PHARMA: CO SAYS VALIDATION OF NIDLEGY MARKETING AUTHORIZATION APPLICATION SUBMISSION BY EMA

ALEMBIC PHARMACEUTICALS: CO RECEIVES USFDA TENTATIVE APPROVAL FOR IVOSIDENIB TABLETS 250 MG -- US SALES USD 114M

FORTIS HEALTHCARE LTD: Rs. 18.13 Crores NSE Block Trade; for ~ 380218 Shares, at Rs. 476.85

FORTIS HEALTHCARE LTD: Rs. 47.99 Crores NSE Block Trade; for ~ 1005298 Shares, at Rs. 477.35

SYNGENE INTERNATIONAL LTD: Rs. 29.49 Crores NSE Block Trade; for ~ 410331 Shares, at Rs. 718.70

ALEMBIC PHARMACEUTICALS: CO HAS CUMULATIVE TOTAL OF 206 ANDA APPROVALS FROM US FDA

ALEMBIC PHARMACEUTICALS: CO RECEIVED 11 USFDA PRODUCT APPROVALS (FINAL & TENTATIVE) DURING THE QUARTER ENDED 30TH JUNE, 2024

ASTRAZENECA PHARMA: CO APPOINTS MR. SRIKANTH B.S. AS SITE LEAD, INDIA OPERATIONS -- PREVIOUSLY WORKED AT DR. REDDY’S

FORTIS HEALTHCARE LTD: Rs. 19.89 Crores NSE Block Trade; for ~ 423283 Shares, at Rs. 470.00

DIVIS LABORATORIES LTD: Rs. 41.63 Crores NSE Block Trade; for ~ 91175 Shares, at Rs. 4565.95

FORTIS HEALTHCARE LTD: Rs. 46.17 Crores NSE Block Trade; for ~ 1005773 Shares, at Rs. 459.05

DIVIS LABORATORIES LTD: Rs. 28.18 Crores NSE Block Trade; for ~ 61516 Shares, at Rs. 4580.40

THYROCARE TECHNOLOGIES: CO SAYS EXECUTION OF BUSINESS TRANSFER AGREEMENT WITH POLO LABS -- CO WOULD BE ACQUIRING POLOS DIAGNOSTIC, PATHOLOGICAL SERVICES BUSINESS; DEAL FOR 42.6M RUPEES

SOLARA ACTIVE PHARMA SCIENCES: CO SAYS TPG GROWTH IV SF CUT STAKE IN CO TO 4.44% FROM 8.60% -- CUT STAKE VIA OPEN MARKET SALE

HEALTHCARE GLOBAL ENTERPRISES: CO SAYS COST OF ACQUISITION OF 51% STAKE AT 2.08B RUPEES -- COST OF ACQUISITION OF ADDITIONAL 34% STAKE AT 1.55B RUPEES

HEALTHCARE GLOBAL ENTERPRISES: CO SAYS ACQUISITION OF SHARES OF VIZAG HOSPITAL AND CANCER RESEARCH CENTRE

MAX HEALTHCARE INSTITUTE: CO SAYS CONSTRUCTION OF 300 BEDDED HOSPITAL COMPLETED

MAX HEALTHCARE: CO COMMENCES OPERATIONS OF MAX SUPER SPECIALITY HOSPITAL, DWARKA

MAX HEALTHCARE INSTITUTE LTD: RS. 92.07 CRORES NSE BLOCK TRADE; FOR ~ 1004614 SHARES, AT RS. 916.50

MARKSANS PHARMA: CO UNIT RECEIVES RELONCHEM MARKETING AUTHORIZATION FROM UK MHRA FOR 2 TABLETS

GLOBAL HEALTH LTD: Rs. 26.00 Crores NSE Block Trade; for ~ 203487 Shares, at Rs. 1277.95

NEULAND LAB: CO HAS TRANSFERRED A PART OF PROPERTY SITUATED AT HYDERABAD BY WAY OF PERPETUAL LEASE, FOR A CONSIDERATION OF RS. 31.50 CR

ZYDUS LIFESCIENCES: CO UNIT GOT RECTIFICATION ORDER DROPPING DEMAND OF 2.85B RUPEES

IOL CHEMICAL: CHINA’S DRUG REGULATORY AUTHORITY HAS APPROVED THE PRODUCT “FENOFIBRATE” MANUFACTURED BY THE CO -- THIS WILL ENABLE THE CO TO EXPORT ITS FENOFIBRATE API IN CHINA MARKET

PANACEA BIOTEC: HV ALLEGED CO IN ALLEGED BREACH OF OBLIGATIONS UNDER TECHNOLOGY TRANSFER AGREEMENT -- CO MAY BE LIABLE TO REFUND $7M PLUS INTEREST THEREON AS MAY BE AWARDED

PANACEA BIOTECH: CO REQUEST FOR ARBITRATION FILED BY HUMAN VACCINE LIMITED LIABILITY COMPANY, RUSSIA

LUPIN: CO COMPLETES TRANSFER OF TRADE GENERICS BUSINESS TO UNIT LUPIN LIFE SCIENCES

DIVIS LABORATORIES LTD: Rs. 22.95 Crores NSE Block Trade; for ~ 50062 Shares, at Rs. 4583.55

AUROBINDO PHARMA LTD: Rs. 28.99 Crores NSE Block Trade; for ~ 238113 Shares, at Rs. 1217.50

TORRENT PHARMACEUTICALS LTD: Rs. 24.43 Crores NSE Block Trade; for ~ 87150 Shares, at Rs. 2802.95

ALEMBIC PHARMA: CO RECEIVED US FOOD & DRUG ADMINISTRATION (USFDA) TENTATIVE APPROVAL FOR BOSUTINIB TABLETS -- US SALES OF 275M USD

BLUE JET HEALTHCARE: CO EXPANDS PRODUCTION CAPACITY WITH NEW PHARMA INTERMEDIATES BLOCK IN MAHARASHTRA, -- ADDS 120 KL TO EXISTING 1020.90 KL CAPACITY WITH INVESTMENT OF RUPEES 90 CR

LAURUS LAB: COMPANY HAS RECEIVED THE ESTABLISHMENT INSPECTION REPORT (EIR), INDICATING CLOSURE OF THE INSPECTION

POLY MEDICURE: CO HAS CONSIDERED AND APPROVED RAISING OF FUNDS NOT EXCEECLING RUPEES 1,000 CRORE BY WAY OF QIP

AUROBINDO PHARMA: CO UNIT ACQUIRED ENTIRE SHARE CAPITAL OF ACE LABORATORIES LIMITED, UK -- COST OF ACQUISITION 179.1M RUPEES

ZYDUS LIFESCIENCES: DR. REDDY’S WILL MARKET IT UNDER THE BRAND NAME WOMAB -- CO TO GET UPFRONT LICENSING INCOME, ELIGIBLE TO RECEIVE MILESTONE INCOME BASED ON ACHIEVEMENT OF MILESTONES

ZYDUS LIFESCIENCES: ZYDUS AND DR. REDDYS ANNOUNCE LICENSING AGREEMENT FOR CO-MARKETING OF PERTUZUMAB BIOSIMILAR -- PRODUCT WILL BE MARKETED BY ZYDUS UNDER THE BRAND NAME SIGRIMA

WOCKHARDT: CO SAYS SUCCESSFUL USE OF INVESTIGATIONAL ANTIBIOTIC, ZAYNICH TO TREAT CANCER PATIENT IN U.S. WITH CHRONIC BILATERAL THIGH INFECTION

WOCKHARDT: CO CHAIRMAN SAYS WILL LAUNCH ZAYNICH IN INDIA EARLY NEXT YEAR - BBG

HEALTHCARE GLOBAL: VIZAG HOSPITAL, OWNS AND OPERATES A COMPREHENSIVE CANCER CARE HOSPITAL IN THE CITY OF VISHAKHAPATNAM, ANDHRA PRADESH, WITH A WELL-BUILT HOSPITAL INFRASTRUCTURE, HAVING 196 OPERATIONAL BEDS FACILITY

HEALTHCARE GLOBAL: CO HAS AGREED UNDER THE PROVISIONS OF THE SPA TO ACQUIRE 51% (FIFTY-ONE PERCENT) OF THE EQUITY SHARE CAPITAL IN VIZAG HOSPITAL

SUNPHARMA: INDIA EYES INCENTIVES FOR LOCAL OBESITY DRUG PRODUCTION IN 2026 -- CO RACES TO DEVELOP ITS OBESITY DRUG AMID GLOBAL CRUNCH - BBG

ALEMBIC PHARMA: CO RECEIVES USFDA FINAL APPROVAL FOR DOXYCYCLINE CAPSULES -- CAPSULES HAS US SALES OF 123M USD

CIPLA LTD: Rs. 30.91 Crores NSE Block Trade; for ~ 208369 Shares, at Rs. 1483.20

KIMS: CO CONSIDERED AND APPROVED THE PROPOSAL FOR THE SUB-DIVISION OF 1 EQUITY SHARE INTO 5 (FIVE)

NARAYANA HRUDAYALAYA LTD: Rs. 26.30 Crores NSE Block Trade; for ~ 218015 Shares, at Rs. 1206.35

LUPIN: CO SAYS EUROPEAN COURT DISMISSED FINAL APPEAL BY CO AGAINST ORDER OF EUROPEAN COMMISSION LEVYING FINE OF EURO 40M

DISHMAN CARBOGEN AMCIS: CO UNIT COMPLETED US FDA INSPECTION OF MANUFACTURING SITES LOCATED IN HUNZENSCHWIL AND AARAU, IN SWITZERLAND -- CO SAYS INSPECTIONS AT BOTH SITES WERE CONCLUDED WITH NO FORM 483 AND CLASSIFIED AS NO ACTION INDICATED

BIOCON: CO IN INVESTOR PRESENTATION SAYS - FY25 GUIDANCE REVENUE GROWTH IN HIGH SINGLE DIGITS TO LOW DOUBLE DIGITS; OPERATING EBITDA MARGINS COMPARABLE TO FY24; SINGLE DIGIT PAT GROWTH -- BIOSIMILARS ARE AN ATTRACTIVE MARKET WITH THE GLOBAL BIOSIMILAR MARKET EXPECTED TO REACH $56B BY 2030

UNICHEM LABORATORIES: CO SAYS COURT OF JUSTICE OF EU UPHELD FINE OF EURO 13.96M (APPROXIMATELY RS 125.62 CRS) ON CO, ITS UNIT NICHE GENERICS -- FINE PERTAINING TO PATENT DISPUTE SETTLEMENT AGREEMENT DONE FOR PERINDOPRIL DRUG MATTER

AUROBINDO PHARMA: CO UNIT HAS RECEIVED ESTABLISHMENT INSPECTION REPORT CLASSIFYING THE FACILITY AS "VOLUNTARY ACTION INDICATED"

GLOBAL HEALTH LTD: Rs. 38.60 Crores NSE Block Trade; for ~ 295438 Shares, at Rs. 1306.60

DR REDDYS LAB: CO UNIT ENTERED INTO A DEFINITIVE AGREEMENT WITH HALEON PLC AND ITS ASSOCIATE COMPANIES -- UNIT TO ACQUIRE NICOTINELL AND RELATED BRANDS -- SA WILL PAY UPFRONT CASH CONSIDERATION OF GBP 458 MILLION

PIRAMAL PHARMA LTD: RS. 63.89 CRORES NSE BLOCK TRADE; FOR ~ 4112658 SHARES, AT RS. 155.36

VIJAYA DIAGNOSTIC CENTRE: MEDINOVA DIAGNOSTIC SERVICES & CO APPROVED SCHEME OF AMALGAMATION

NEULAND LAB: Rs 96.2cr BSE Block Trade; for ~130000 shares, at Rs 7400 (PRE-OPEN BLOCK)

SHILPA MEDICARE: USFDA HAS CONCLUDED THAT THE INSPECTION HAS NOW BEEN CLOSED WITH THE ISSUANCE OF THE ESTABLISHMENT INSPECTION REPORT (EIR) -- THE FACILITY IS CLASSIFIED AS “NO ACTION INDICATED

JUBILANT PHARMOVA: CO INFORMS REGARDING VOLUNTARY PREPAYMENT OF USD 75 MILLION TERM LOAN, EQUIVALENT TO RS. 626 CR BY SUBSIDIARY CO IN U.S

ALKEM LABS: CO SAYS CLOSURE OF US FDA INSPECTION AT COS MANUFACTURING FACILITY LOCATED AT BADDI -- INSPECTION HAS BEEN CLASSIFIED AS VOLUNTARY ACTION INDICATED AND HAS BEEN CLOSED ACCORDINGLY

FORTIS HEALTHCARE LTD: RS. 73.13 CRORES NSE BLOCK TRADE; FOR ~ 1505498 SHARES, AT RS. 485.75

CIPLA: CO SAYS USFDA VOLUNTARY ACTION INDICATED FOR PATALGANGA FACILITY

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA ISSUES VOLUNTARY NATIONWIDE RECALL FOR POTASSIUM CHLORIDE EXTENDED-RELEASE CAPSULES, USP (750 MG) 10 MEQ K DUE TO FAILED DISSOLUTION - RTRS

KRISHNA INSTITUTE OF MEDICAL SCIENCES: BOARD MEETING ON JUNE 28 TO CONSIDER SUB-DIVISION/SPLIT OF SHARES IN 1:5 RATIO

SHALBY: CO TERMINATED FRANCHISE AGREEMENT WITH MADHUBAN ORTHOPEDIC AND MULTISPECIALTY SURGICAL HOSPITAL

SUN PHARMA: CO SAYS COMBINED ENTITY IS BETTER POSITIONED TO COMPETE IN INCREASINGLY COMPETITIVE GENERICS INDUSTRY

SUN PHARMA: CO SUCCESSFULLY COMPLETED THE MERGER OF TARO PHARMACEUTICAL INDUSTRIES WITH ITS SUBSIDIARY -- TARO IS NOW A PRIVATE COMPANY AND WHOLLY-OWNED BY SUN PHARMA

ASTER DM HEALTHCARE: OLYMPUS CAPITAL ASIA INVESTMENTS CUTS STAKE IN CO BY 9.01% TO HOLD 1.09% STAKE - EXCHANGE FILING

CIPLA: CO SAYS USFDA HAS CONDUCTED AN INSPECTION AT THE CO’S MANUFACTURING FACILITY IN GOA -- CO SAYS ON CONCLUSION OF THE INSPECTION, CO RECEIVED 6 INSPECTIONAL OBSERVATIONS IN FORM 483

DIVIS LABORATORIES: NSE CIRCULAR - DIVIS LABORATORIES AND TRENT LTD NOT AVAILABLE FOR TRADING IN T+0 ROLLING SETTLEMENT CYCLE ON JUNE 24

BLISS GVS PHARMA: CO GETS ORDER FOR SUSPENSION OF FDA LICENSE ISSUED TO COS TABLET DIVISION OF MANUFACTURING UNIT AT PALGHAR (WEST) -- ORDER FOR SUSPENSION OF FDA LICENSE FOR 5 DAYS IN AUGUST 2024

ASTRAZENECA PHARMA: CO WILL NOW EXPLORE A BUYER FOR ITS MANUFACTURING SITE AND EXIT IN DUE COURSE

ASTRAZENECA PHARMA: CO COMPLETED EXPLORATION PHASE FOR SEARCH OF BUYER WHO COULD ACT AS CONTRACT MANUFACTURING ORGANISATION

POLY MEDICURE LTD: RS. 451.13 CRORES NSE BLOCK TRADE; FOR ~ 2293906 SHARES, AT RS. 1966.65

ASTER DM HEALTHCARE: RS 1556.07CR BSE BLOCK TRADE; FOR ~45077282 SHARES, AT RS 345.2

SUN PHARMA: CO SIGNS NON-EXCLUSIVE PATENT LICENSING AGREEMENT WITH TAKEDA FOR INTRODUCING NOVEL GASTROINTESTINAL DRUG, VOLTAPRAZ (VONOPRAZAN) IN INDIA

ASTER DM HEALTHCARE: OLYMPUS CAPITAL ASIA INVESTMENT LIKELY TO SELL 10.1% EQUITY IN ASTER DM TOMORROW -- THE BLOCK INCLUDES A BASE SIZE OF 5.05% WITH AN UPSIZE OPTION OF 10.1% -- FLOOR PRICE AT 331 RUPEES/SH (7.1% DISCOUNT TO CMP) -- DEAL SIZE OF THE BLOCK IS 835 CRORE RUPEES, UPSIZE AT 1,670 CRORE RUPEES - CNBCTV18, CITING SOURCES

SUN PHARMA: CO SAYS DADRA FACILITY RECEIVES WARNING LETTER FROM US FDA -- CO SAYS WARNING LETTER SUMMARIZES VIOLATIONS WITH RESPECT TO CURRENT GOOD MANUFACTURING PRACTICE REGULATIONS

ADVANCED ENZYME TECHNOLOGIES LTD: RS. 420.60 CRORES BSE BLOCK TRADE; FOR ~ 10924787 SHARES, AT RS. 385 (INSTITUTIONAL BLOCK)

ADVANCED ENZYME TECHNOLOGIES LTD: RS. 420.60 CRORES BSE BLOCK TRADE; FOR ~ 10924787 SHARES, AT RS. 385.00

DR REDDYS LABORATORIES LTD: Rs. 16.00 Crores NSE Block Trade; for ~ 26993 Shares, at Rs. 5928.00

GLAND PHARMA: RS 844.78CR BSE BLOCK TRADE; FOR ~4769957 SHARES, AT RS 1771.05

GLAND PHARMA: RS 178.76CR BSE BLOCK TRADE; FOR ~1009334 SHARES, AT RS 1771.05

ZYDUS LIFESCIENCES: ZYNEXT VENTURES, THE VC ARM OF ZYDUS LIFESCIENCES, ANNOUNCES INVESTMENT IN PROMAXO: PIONEERING POINT-OF-CARE MEDICAL IMAGING AND INTERVENTIONS WITH NEXT GENERATION MRI SYSTEMS

AMI ORGANICS: CO SAYS APPROVED FLOOR PRICE FOR QUALIFIED INSTITUTIONS PLACEMENT OF SHARES AT 1228.71 RUPEES PER SHARE

GLAND PHARMA: FOSUN PHARMA INDUSTRIAL PTE LIKELY TO SELL UP TO 8.2M SHARES (5% EQ) OF GLAND PHARMA -- FLOOR PRICE AT 1750 RUPEES/SH (AT A DISCOUNT OF 4.9% TO CMP) -- OFFER SIZE OF THE DEAL IS $172M -- THERE IS LOCK IN PERIOD OF 90 DAYS ON THE SELLER - CNBCTV18, CITING SOURCES

JUBILANT PHARMOVA: CO SAYS USFDA HAS ISSUED 15 OBSERVATIONS PURSUANT TO THE COMPLETION OF AUDIT AT MANUFACTURING FACILITY AT MONTREAL, CANADA

CIPLA: CO EU TO INVEST AN ADDITIONAL EUR 3 MILLION IN ETHRIS

ALEMBIC PHARMACEUTICALS: CO RECEIVES USFDA FINAL APPROVAL FOR DABIGATRAN ETEXILATE CAPSULES AND TENTATIVE APPROVAL FOR DABIGATRAN ETEXILATE CAPSULES

ALKEM LAB: RS 991.21CR BSE BLOCK TRADE; FOR ~2000017 SHARES, AT RS 4956

JUBILANT PHARMOVA: CO SAYS INVESTMENT WILL EXPAND COS PET RADIOPHARMACY NETWORK TO NINE SITES, OVERALL RADIOPHARMACY NETWORK TO FIFTY TWO SITES

JUBILANT PHARMOVA: CO UNIT ANNOUNCED AN INVESTMENT OF $50M TO EXPAND ITS PET RADIOPHARMACY NETWORK -- CO SAYS ADDING SIX PET RADIOPHARMACIES IN STRATEGIC LOCATIONS THROUGHOUT UNITED STATES

JUBILANT PHARMOVA: CO UNIT ISSUED A NOTICE TO ITS LENDERS TO VOLUNTARY PREPAY $75 MILLION TERM LOAN, EQUIVALENT TO 6.26 BLN RUPEES

SUPRIYA LIFESCIENCE: CO SAYS RAJEEV KUMAR JAIN WILL CEASE TO BE CHIEF EXECUTIVE OFFICER

SUN PHARMA: CO INFORMS ABOUT ORAL PRESENTATION AT EULAR 2024 OF DATA FROM GLOBAL PHASE 2B CLINICAL TRIAL DEMONSTRATES DURABILITY OF PAIN RELIEF AFTER A SINGLE INJECTION OF MM-II IN PATIENTS WITH PAINFUL KNEE OSTEOARTHRITIS (OA)

ZYDUS LIFESCIENCES: CO RECEIVES TENTATIVE APPROVAL FROM USFDA FOR AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE TABLETS -- TABLETS HAS US SALES OF 78M USD

LUPIN: USFDA ISSUES FORM 483 WITH ZERO OBSERVATION TO ITS NAGPUR UNIT

SUVEN PHARMACEUTICALS: CO EXECUTED DEFINITIVE AGREEMENTS FOR ACQUIRING 100% OF SHARES IN SAPALA ORGANICS; DEAL FOR 2.3B RUPEES -- CO AGREED TO INITIALLY ACQUIRE 67.5% BY WAY OF SECONDARY TRANSFER FROM SAPALA ORGANICS EXISTING SHAREHOLDERS

TORRENT PHARMA: CO UPDATES USFDA COMPLETES INSPECTION OF INDRAD, GUJARAT FACILITY WITH FIVE OBSERVATIONS

DR REDDYS LABORATORIES: CO UNIT AND INGENUS PHARMACEUTICALS, LLC HAVE ENTERED INTO LICENSE AGREEMENT -- CO UNIT OBTAINED EXCLUSIVE RIGHTS TO COMMERCIALIZE CYCLOPHOSPHAMIDE INJECTION RTD (500 MG/2.5ML; 1G/5ML; 2G/10ML) IN U.S. -- SALES OF THE SAID INGENUS PRODUCT AS PER THE IQVIA FOR THE PAST 12 MONTHS ENDED MARCH 2024 WAS $51.8M

DR REDDYS LABORATORIES: CO UNIT AND INGENUS PHARMACEUTICALS, LLC HAVE ENTERED INTO LICENSE AGREEMENT -- CO UNIT OBTAINED EXCLUSIVE RIGHTS TO COMMERCIALIZE CYCLOPHOSPHAMIDE INJECTION RTD (500 MG/2.5ML; 1G/5ML; 2G/10ML) IN U.S.

ALKEM LABORATORIES LTD: Rs. 25.90 Crores NSE Block Trade; for ~ 51080 Shares, at Rs. 5071.45

GLENMARK PHARMA: CO RECEIVES ANDA APPROVAL FOR ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES -- CAPSULES HAS ACHIEVED ANNUAL SALES OF APPROXIMATELY USD 259.2M

CIPLA: CO SAYS ADDITIONAL COMMISSIONER OF STATE TAX UPHELD ORDER OF OFFICE OF JOINT COMMISSIONER OF STATE TAXES AGAINST CO -- CO SAYS WILL FILE NECESSARY APPEAL WITH THE HIGHER APPELLATE AUTHORITY IN THIS REGARD

IOL CHEMICALS AND PHARMACEUTICALS: CO SAYS EDQM ISSUED CEP CERTIFICATE FOR “ALLOPURINOL”

IOL CHEMICALS AND PHARMACEUTICALS: CO SAYS EDQM ISSUED CEP CERTIFICATE FOR "PANTOPRAZOLE SODIUM SESQUIHYDRATE" FOR ALTERNATIVE PROCESS (PROCESS - II) -- CO SAYS CERTIFICATION WILL ENABLE CO TO EXPORT PRODUCT IN EUROPEAN AND OTHER CEP ACCEPTING COUNTRIES

BIOCON: CO HAS APPROVED THE APPOINTMENT OF MR MUKESH KAMATH, HEAD - BUSINESS FINANCE R&D, AS THE INTERIM CFO -- MR MUKESH HAS WORKED ON VARIOUS ROLES WITH UNITED BREWERIES

POLY MEDICURE LTD: Rs. 34.54 Crores NSE Block Trade; for ~ 187793 Shares, at Rs. 1839.30

MAX HEALTHCARE INSTITUTE LTD: Rs. 16.74 Crores NSE Block Trade; for ~ 201896 Shares, at Rs. 829.25

GLENMARK: FITCH RATINGS SAYS THEY BELIEVE COS ROBUST GROWTH IN INDIA, OTHER MARKETS WILL IMPROVE ITS PROFITABILITY FROM FY24

GLENMARK PHARMA: FITCH AFFIRMS CO AT BB; OUTLOOK STABLE

JUBILANT PHARMOVA: CO ANNOUNCES COMPLETION OF USFDA AUDIT OF CONTRACT MANUFACTURING FACILITY AT SPOKANE, WASHINGTON -- USFDA HAS ISSUED 3 OBSERVATIONS PURSUANT TO COMPLETION OF AUDIT; CO WILL SUBMIT AN ACTION PLAN ON OBSERVATIONS

LUPIN: CO ENTERS INTO BUSINESS TRANSFER AGREEMENT WITH UNIT LUPIN LIFE SCIENCES TO CARVE OUT OF COS TRADE GENERICS BUSINESS IN INDIA WILL BE EFFECTIVE JULY 1, 2024

DR REDDYS LABORATORIES: CO SAYS WE HAVE BEEN ISSUED A FORM 483 WITH FOUR OBSERVATIONS, WHICH WE WILL ADDRESS WITHIN THE STIPULATED TIMELINE

DR REDDYS LABORATORIES: CO SAYS COMPLETED A GMP INSPECTION AT OUR API MANUFACTURING FACILITY (CTO-6) IN SRIKAKULAM, ANDHRA PRADESH -- CO SAYS THE INSPECTION WAS CONDUCTED FROM MAY 30, 2024 TO JUNE 7, 2024

AMI ORGANICS: CO SAYS UNIT I SITUATED AT SACHIN, SURAT WHICH IS INVOLVED IN MANUFACTURING OF VARIOUS INTERMEDIATES FOR ACTIVE PHARMACEUTICALS INGREDIENTS, HAS UNDERGONE A GOOD MANUFACTURING PRACTICES (GMP) INSPECTION BY PHARMACEUTICAL AND MEDICAL DEVICES AGENCY, JAPAN (PMDA) STARTING JUNE 4, 2024 -- CO SAYS THE INSPECTION HAS CONCLUDED SUCCESSFULLY ON JUNE 7, 2024 WITHOUT ANY CRITICAL/MAJOR OBSERVATION

GLAND PHARMA: CO SAYS SRINIVAS SADU APPOINTED AS EXECUTIVE CHAIRMAN AND CEO OF GLAND PHARMA

MANKIND PHARMA LTD: RS. 250.30 CRS NSE BLOCK TRADE; FOR ~ 1184561 SHARES, AT RS. 2113.00

APOLLO HOSPITALS ENTERPRISE LTD: Rs. 24.80 Crores NSE Block Trade; for ~ 41313 Shares, at Rs. 6003.95

JB CHEMICALS & PHARMACEUTICALS LTD: Rs. 23.60 Crores NSE Block Trade; for ~ 132387 Shares, at Rs. 1782.70

SUN PHARMA: CO TO ACQUIRE 9.6% STAKE IN HEALTHCARE CO HAYSTACKANALYTICS FOR RUPEES 33 CR

JUBILANT PHARMOVA: CO HAS ACQUIRED THE REMAINING STAKE IN O2 UPON SUCCESSFUL COMPLETION OF MILESTONES AND ACCORDINGLY THE ACQUISITION OF 19.89% STAKE IN O2 HAS BEEN COMPLETED

ALKEM LABORATORIES:CO AGREED TO INVEST 300 MLN RUPEES IN SHARES OF HAYSTACKANALYTICS -- PROPOSED INVESTMENT WILL HELP CO TO PARTICIPATE IN GROWING DIAGNOSTIC SPACE

INDOCO REMEDIES: CO RECEIVES TENTATIVE ANDA APPROVAL FROM USFDA FOR CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE TABLETS

CONCORD BIOTECH: CO SAYS HEALTH PRODUCT REGULATORY AUTHORITY OF IRELAND HAS ISSUED EUGMP CERTIFICATE FOR COS UNIT II AT DHOLKA, AHMEDABAD

UNICHEM LABORATORIES: AXSOME THERAPEUTICS SETTLES SUNOSI® (SOLRIAMFETOL) PATENT LITIGATION WITH UNICHEM LABORATORIES

TORRENT PHARMACEUTICALS: CO ENTERS INTO NON-EXCLUSIVE PATENT LICENSING AGREEMENT WITH TAKEDA PHARMACEUTICALS TO COMMERCIALIZE ITS NOVEL GASTROINTESTINAL DRUG IN INDIA

JUBILANT PHARMOVA: CO UPDATE ON DISPOSAL OF INVESTMENT IN SOFIE BIOSCIENCES BY CO -- CO HAS RECEIVED USD 115.9M AS A PART OF THE CONSIDERATION

GLAND PHARMA LTD: Rs. 17.16 Crores NSE Block Trade; for ~ 93006 Shares, at Rs. 1845.00

JB CHEMICALS & PHARMACEUTICALS LTD: Rs. 22.19 Crores NSE Block Trade; for ~ 126201 Shares, at Rs. 1758.00

LUPIN: CO COMPLETES ACQUISITION OF TWO BRANDS FROM SANOFI IN EUROPE AND CANADA

FORTIS HEALTHCARE LTD: Rs. 21.84 Crores NSE Block Trade; for ~ 501035 Shares, at Rs. 435.95

SHILPA MEDICARE: CO UNIT FILED DRUG MASTER FILE OF RECOMBINANT HUMAN ALBUMIN 20% WITH USFDA

SUNPHARMA: CO SAYS NIDLEGY™ MARKETING AUTHORIZATION APPLICATION SUBMITTED TO EMA

DR REDDYS LABORATORIES: CO UNIT AURIGENE PHARMACEUTICAL SERVICES LTD, A GLOBAL CRDMO, ANNOUNCES THE OPENING OF ITS BIOLOGICS FACILITY OFFERING PROCESS DEVELOPMENT AND CLINICAL SCALE MANUFACTURING CAPABILITIES

BIOCON: CO HAS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (US FDA), FOR ITS VERTICALLY INTEGRATED, COMPLEX INJECTABLE DRUG PRODUCT, MICAFUNGIN (50MG AND 100MG VIALS), USED AS AN ANTIFUNGAL MEDICATION TO TREAT FUNGAL OR YEAST INFECTIONS

ALKEM LABORATORIES LTD: RS. 102.70 CRORES NSE BLOCK TRADE; FOR ~ 213643 SHARES, AT RS. 4807.30

ADVANCED ENZYME TECHNOLOGIES LTD: Rs. 15.03 Crores NSE Block Trade; for ~ 421070 Shares, at Rs. 356.90

SMS PHARMA: CO SAYS TOP-LINE GROWTH IS EXPECTED TO BE AROUND 20% TO 25% FOR FY25 -- CO SAYS GROSS MARGIN GROWTH IS EXPECTED TO BE AROUND 25% FOR FY 2025 - CONCALL UPDATES

AUROBINDO PHARMA: CO SAYS AGREEMENT FOR EXPLORING POSSIBILITIES TO ENTER INTO CONTRACT MANUFACTURING OPERATIONS FOR BIOLOGICALS -- THERANYM WILL INVEST AROUND 10 BLN RUPEES FOR ESTABLISHING MANUFACTURING FACILITY

AUROBINDO PHARMA: CO SAYS THERANYM BIOLOGICS AND MSD SIGNED A MASTER SERVICE AGREEMENT -- AGREEMENT FOR EXPANSION OF BIOLOGICS MANUFACTURING FACILITIES OF THERANYM

ZYDUS LIFESCIENCES: CO UNIT APPROVED SHARE PURCHASE AGREEMENT FOR ACQUIRING SHARES OF ZYDUS MEDTECH

GRANULES INDIA LTD: RS. 50.39 CRORES NSE BLOCK TRADE; FOR ~ 1200736 SHARES, AT RS. 419.65

SUVEN PHARMACEUTICALS LTD: Rs. 18.60 Crores NSE Block Trade; for ~ 300629 Shares, at Rs. 618.65

GLAND PHARMA LTD: Rs. 20.90 Crores NSE Block Trade; for ~ 112769 Shares, at Rs. 1853.00

IPCA LAB: CO SAYS DOMESTIC BUSINESS EXPECTED TO GROW AROUND 12% - CONCALL UPDATE

IPCA LAB: CO SAYS GUIDANCE FOR FY25: STANDALONE BUSINESS GROWTH OF 10.5% TO 11%, EBITDA MARGINS IMPROVING TO 20.5% TO 21%, CONSOLIDATED BUSINESS GROWTH OF 14% TO 14.25%, AND CONSOLIDATED EBITDA IMPROVING TO 18% - CONCALL UPDATE

GUFIC BIOSCIENCES: CO SAYS REVENUE GROWTH EXPECTED BETWEEN 15% TO 20% YEAR-OVER-YEAR FOR THE NEXT 3 TO 4 YEARS - CONCALL UPDATE

SUVEN PHARMA: CO SAYS GUIDANCE FOR FY 25 IS POSITIVE, WITH MID-TERM TO LONG-TERM GROWTH EXPECTED -- CO EXPECTS TO SEE GROWTH BOTH IN REVENUE AND EBITDA FOR THE FULL YEAR OF 25, WITH GROWTH ACCELERATING IN FY 26 - CONCALL UPDATES

GLENMARK PHARMACEUTICALS: CO IN INVESTOR PRESENTATION SAYS - ESTIMATED TOTAL ANNUAL GLOBAL SALES OF US$ 300 – 400 MILLION OVER THE NEXT FIVE YEARS -- OVERALL CASH BURN FOR IGI WILL REDUCE TO ~US$ 50 MILLION STARTING FY25

DISHMAN CARBOGEN AMCIS: Q4 EBITDA 629M RUPEES VS 510M (YOY) -- Q4 EBITDA MARGIN 9.60% VS 8.26% (YOY)

DISHMAN CARBOGEN AMCIS: Q4 CONS NET LOSS 699M RUPEES VS LOSS 707M (YOY) -- Q4 REVENUE 6.5B RUPEES VS 6.2B (YOY)

KRISHNA INSTITUTE OF MEDICAL SCIENCES: CO ANNOUNCES EXPANSION BY SETTING UP OF 350 BED SUPER SPECIALTY HOSPITAL IN BENGALURU, KARNATAKA -- UNIT ENTERED INTO AGREEMENT WITH PES TO EXCLUSIVELY MANAGE PROPOSED UNDER-CONSTRUCTION HOSPITAL UNIT

KRISHNA INSTITUTE OF MEDICAL SCIENCES: CO UNIT ENTERED INTO A DEFINITIVE AGREEMENTS WITH PEOPLE EDUCATION SOCIETY (PES) -- DEFINITIVE AGREEMENTS TOWARDS LEASE OF LAND AND HOSPITAL BUILDING FOR A PERIOD OF 25 YEARS

SUN PHARMA: CO ACCEPTED PREFERENTIAL OFFER TO ACQUIRE 14.28% SHARES OF INDIAN FOUNDATION FOR QUALITY MANAGEMENT -- COST OF ACQUISITION 125 MLN RUPEES

NATCO PHARMA: CO ANNOUNCES SUBMISSION OF ABBREVIATED NEW DRUG APPLICATION (ANDA) CONTAINING A PARAGRAPH IV CERTIFICATION WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE GENERIC VERSION OF RIMEGEPANT SULFATE TABLET EQ 75MG BASE STRENGTH

LAURUS LABS: WILLOW BIOSCIENCES INC ANNOUNCES MULTI-PRODUCT DEVELOPMENT AND LICENSING PARTNERSHIP WITH LAURUS LABS

SASTASUNDAR VENTURES: Q4 REVENUE 3.07B RUPEES VS 3.13B (YOY)

SASTASUNDAR VENTURES: Q4 CONS NET PROFIT 164.4M RUPEES VS LOSS 342M (YOY)

APOLLO HOSPITALS ENTERPRISE: CO RECOMMENDED A FINAL DIVIDEND OF 10 RUPEES PER EQUITY SHARE

APOLLO HOSPITALS ENTERPRISE: Q4 EBITDA 6.41B RUPEES VS 4.88B (YOY); EST 6.23B -- Q4 EBITDA MARGIN 12.96% VS 11.35% (YOY); EST 12.7%

APOLLO HOSPITALS ENTERPRISE: Q4 REVENUE 49.4B RUPEES VS 43B (YOY); EST 48.86B

APOLLO HOSPITALS ENTERPRISE: Q4 CONS NET PROFIT 2.54B RUPEES VS 1.45B (YOY); EST 2.50B

SUVEN PHARMA: Q4 EBITDA 733.4M RUPEES VS 1.72B (YOY) -- Q4 EBITDA MARGIN 29% VS 46.53% (YOY)

SUVEN PHARMA: Q4 REVENUE 2.53B RUPEES VS 3.7B (YOY)

SUVEN PHARMA: Q4 CONS NET PROFIT 533.7M RUPEES VS 1.24B (YOY)

PANACEA BIOTEC: Q4 REVENUE 1.36B RUPEES VS 1.29B (YOY)

PANACEA BIOTEC: Q4 CONS NET LOSS 14M RUPEES VS LOSS 124M (YOY)

TARSONS PRODUCTS: Q4 EBITDA 339M RUPEES VS 393M (YOY) -- Q4 EBITDA MARGIN 39.10% VS 47.84% (YOY)

TARSONS PRODUCTS: Q4 REVENUE 866M RUPEES VS 820M (YOY)

TARSONS PRODUCTS: Q4 SL NET PROFIT 188M RUPEES VS 228M (YOY)

ALEMBIC PHARMACEUTICALS: CO RECEIVES USFDA FINAL APPROVAL FOR SACUBITRIL AND VALSARTAN TABLETS -- SACUBITRIL AND VALSARTAN TABLETS HAS US SALES OF 5.3B USD

MARKSANS PHARMA: Q4 EBITDA 1.09B RUPEES VS 1.10B (YOY) -- Q4 EBITDA MARGIN 19.58% VS 22.54% (YOY)

MARKSANS PHARMA: Q4 CONS NET PROFIT 789M RUPEES VS 819M (YOY)

MARKSANS PHARMA: Q4 CONS NET PROFIT 789M RUPEES VS 819M (YOY)

POLY MEDICURE LTD: RS. 59.37 CRORES NSE BLOCK TRADE; FOR ~ 323414 SHARES, AT RS. 1835.70

SOLARA ACTIVE PHARMA: CO WILL HIT ITS HISTORICAL HIGHS OF ITS EBITDA IN THE NEXT 6 QUARTERS TO 8 QUARTERS -- CO EXPECTS CASH GENERATION TO BE GREATER THAN EBITDA, LEADING TO A SIGNIFICANT DEBT REDUCTION FROM OPERATIONS - CONCALL UPDATES

SOLARA ACTIVE PHARMA: CO SAYS GUIDANCE FOR THE YEAR IS A REVENUE GROWTH OF APPROXIMATELY INR1,500 CRORES AND AN EBITDA RUN-RATE OF AROUND INR260 CRORES -- INR290 CRORES - CONCALL UPDATE

ALKEM LAB: CO PROVIDED GUIDANCE FOR FY 25, INCLUDING REVENUE GROWTH OF 7% TO 8% FROM NEW PRODUCT LAUNCHES IN THE US MARKET - CONCALL UPDATE

GUFIC BIOSCIENCES: Q4 EBITDA 342.3M RUPEES VS 321.5M (YOY) -- Q4 EBITDA MARGIN 17.55% VS 18.58% (YOY)

GUFIC BIOSCIENCES: Q4 REVENUE 1.95B RUPEES VS 1.73B (YOY)

GUFIC BIOSCIENCES: Q4 SL NET PROFIT 200M RUPEES VS 181M (YOY)

HEALTHCARE GLOBAL ENTERPRISES: CO HAS EXCEPTIONAL ITEM OF 39M RUPEES

HEALTHCARE GLOBAL ENTERPRISES: Q4 EBITDA 920.3M RUPEES VS 763M (YOY) -- Q4 EBITDA MARGIN 18.66% VS 17.31% (YOY)

HEALTHCARE GLOBAL ENTERPRISES: Q4 REVENUE 4.93B RUPEES VS 4.41B (YOY)

HEALTHCARE GLOBAL ENTERPRISES: Q4 CONS NET PROFIT 212.6M RUPEES VS 84M (YOY)

FDC: Q4 EBITDA 563.2M RUPEES VS 489M (YOY) -- Q4 EBITDA MARGIN 12.19% VS 11.26% (YOY)

FDC: Q4 REVENUE 4.62B RUPEES VS 4.35B (YOY)

FDC: Q4 CONS NET PROFIT 462.8M RUPEES VS 307M (YOY)

SOLARA ACTIVE PHARMA SCIENCES: CO HAS EXCEPTIONAL ITEM OF LOSS 1.22B RUPEES

SOLARA ACTIVE PHARMA SCIENCES: Q4 EBITDA 97.6M RUPEES VS 487.6M (YOY) -- Q4 EBITDA MARGIN 3.26% VS 12.81% (YOY)

SOLARA ACTIVE PHARMA SCIENCES: Q4 REVENUE 2.99B RUPEES VS 3.8B (YOY)

SOLARA ACTIVE PHARMA SCIENCES: Q4 CONS NET LOSS 2.55B RUPEES VS PROFIT 38M (YOY)

JUBILANT PHARMOVA: CO’S WHOLLY OWNED SUBSIDIARY ‘JPL’ PLANS TO SELL ITS 25.8% STAKE IN SOFIE BIOSCIENCES INC. (‘SOFIE’) AT AN AGGREGATE VALUE OF USD 143.27M OR 1200CR RUPEES

JUBILANT PHARMOVA: CO STARTING PHASE II CLINICAL TRIAL TO TREAT ET AND MPN PATIENTS WITH THROMBOCYTOSIS IN H1 2024

JUBILANT PHARMOVA: Q4 EBITDA 2.71B RUPEES VS 2.19B (YOY) -- Q4 EBITDA MARGIN 15.43% VS 13.20% (YOY)

JUBILANT PHARMOVA: Q4 CONS NET LOSS 590M RUPEES VS LOSS 978M (YOY)

ALKEM LABORATORIES: US SALES FOR Q4FY24 STOOD AT WITNESSING A YOY GROWTH OF 5.5%

ALKEM LABORATORIES: Q4 EBITDA 4B RUPEES VS 3.5B (YOY); EST 4.8B -- Q4 EBITDA MARGIN 13.69% VS 12.17% (YOY); EST 15%

ALKEM LABORATORIES: Q4 REVENUE 29.3B RUPEES VS 29B (YOY)

ALKEM LABORATORIES: Q4 EBITDA 4B RUPEES VS 3.5B (YOY) -- Q4 EBITDA MARGIN 13.69% VS 12.17% (YOY)

ALKEM LABORATORIES: Q4 CONS NET PROFIT 2.9B RUPEES VS 710M (YOY)

IPCA LAB: CO FY24 BRANDED BUSINESS REVENUE GROWTH AT 4% VS GUIDANCE OF 8%

IPCA LABORATORIES: Q4 EBITDA 3.2B RUPEES VS 1.8B (YOY) -- Q4 EBITDA MARGIN 15.83% VS 11.98% (YOY)

IPCA LAB: CO HAS EXCEPTIONAL LOSS OF 1.4B RUPEES -- Q4 PROFIT BEFORE TAX SEEN AT 2B VS 1.3B (YOY)

IPCA LABORATORIES: Q4 REVENUE 20B RUPEES VS 15.1B (YOY)

IPCA LABORATORIES: Q4 CONS NET PROFIT 595M RUPEES VS 765M (YOY)

SMS PHARMA: Q4 EBITDA 336M RUPEES VS 232M (YOY)

SMS PHARMA: Q4 REVENUE 2.5B RUPEES VS 1.49B (YOY)

SMS PHARMA: Q4 CONS NET PROFIT 173M RUPEES VS 62M (YOY)

NATCO PHARMA: CO IS LAUNCHING NEW PRODUCTS IN THE NEXT FEW YEARS, BUT THE EXACT TIMING CANNOT BE DISCLOSED DUE TO CONFIDENTIALITY AGREEMENTS - CONCALL UPDATE

NATCO PHARMA: CO PLANS TO SPEND RUPEES 300 CRS TO 350 CRS PER YEAR ON MAINTENANCE CAPEX - CONCALL UPDATE

NATCO PHARMA: CO IS CONSIDERING BUYBACKS IF THEY ARE UNABLE TO CLOSE A LARGE ACQUISITION DEAL - CONCALL UPDATE

NATCO PHARMA: COS GUIDANCE FOR FY25 IS FOR REVENUE GROWTH OF 15% TO 20% AND EARNINGS GROWTH OF 20% - CONCALL UPDATE

NATCO PHARMA: CO IS CONSISTENT IN ITS PERFORMANCE, WITH THE BUSINESS GROWING AT 8-10% - CONCALL UDPATE

DR REDDYS LAB: CO UNIT GETS ORDER FROM GST AUTHORITY TOWARDS TAX DEMAND INCLUDING INTEREST AND PENALTY -- CO UNIT GETS ORDER FROM GST AUTHORITY LEVYING PENALTY OF 19M RUPEES

WOCKHARDT: Q4 REVENUE 7B RUPEES VS 6.78B (YOY)

WOCKHARDT: Q4 CONS NET LOSS 1.69B RUPEES VS LOSS 2.08B (YOY)

ASTER DM HEALTHCARE: CO RECOMMENDED DIVIDEND OF 2 RUPEES PER SHARE

ASTER DM HEALTHCARE: Q4 EBITDA 1.56B RUPEES VS 1.20B (YOY) -- Q4 EBITDA MARGIN 16.07% VS 14.87% (YOY)

ASTER DM HEALTHCARE: Q4 REVENUE 9.74B RUPEES VS 8.07B (YOY)

ASTER DM HEALTHCARE: Q4 CONS NET LOSS 240.3M RUPEES VS PROFIT 1.71B (YOY)

SUPRIYA LIFESCIENCE: Q4 EBITDA 555.1M RUPEES VS 550.5M (YOY) -- Q4 EBITDA MARGIN 35.09% VS 38.69% (YOY)

SUPRIYA LIFESCIENCE: Q4 REVENUE 1.58B RUPEES VS 1.42B (YOY)

SUPRIYA LIFESCIENCE: Q4 SL NET PROFIT 369.3M RUPEES VS 382M (YOY)

SHALBY: Q4 REVENUE 2.44B RUPEES VS 1.98B (YOY)

SHALBY: Q4 EBITDA 389M RUPEES VS 257M (YOY) -- Q4 EBITDA MARGIN 15.93% VS 12.89% (YOY)

SHALBY: Q4 CONS NET PROFIT 166M RUPEES VS 139M (YOY)

MARKSANS PHARMA: CO UNIT RELONCHEM, RECEIVES MARKETING AUTHORISATION FOR THE PRODUCT LEVETIRACETAM RELONCHEM ORAL SOLUTION FROM UK MHRA

GLOBAL HEALTH LTD: RS. 80.81 CRORES NSE BLOCK TRADE; FOR ~ 656193 SHARES, AT RS. 1231.45

LAURUS LABS: CO EXEC SAYS HOPE TO DO 20%+ MARGIN IN FY25 - CNBC TV 18

CONCORD BIOTECH LTD: RS. 497.44 CRORES NSE BLOCK TRADE; FOR ~ 3565854 SHARES, AT RS. 1395.00

NARAYANA HRUDYALAYA: CO SAYS GUIDANCE FOR FY28: REVENUE: RUPEES 1,000 CRORES - CONCALL UPDATE

SIGACHI INDUSTRIES: CO PLANS TO EXPAND THE CONVEX CAPACITY BY 150%, ADDING UP NEARLY 150,000, AT THE END OF WHICH THE TOTAL CAPACITY WILL BE 250,000 - CONCALL UPDATE

SIGACHI INDUSTRIES: CO SAYS GUIDANCE FOR FY 25: REVENUE: RUPEES 301.5 CRORES; EBITDA MARGIN: 25% FOR API SEGMENT -- CO EXPECTS TO REACH 50% CAPACITY UTILIZATION BY Q4- CONCALL UPDATES

AUROBINDO PHARMA: CO SAYS FY 26 IS EXPECTED TO BE BETTER, WITH ONCOLOGY OSDS AND OTHER SIGNIFICANT FILINGS CONTRIBUTING TO GROWTH - CONCALL UPDATE

AUROBINDO PHARMA: CO SAYS GLOBAL REVENUE IS EXPECTED TO BE USD 150M -- EUROPE REVENUE IS EXPECTED TO BE ABOVE EUR 200M IN FY 25 - CONCALL UPDATE

AUROBINDO PHARMA: CO PROVIDED GUIDANCE FOR EBITDA MARGIN TARGET SET INTERNALLY FOR THE YEAR FY 25 AT 21% TO 22% -- CO EXPECTS TO MAINTAIN A RUN RATE OF AROUND USD 150M EVERY YEAR ACROSS THE GLOBE - CONCALL UPDATE

GLENMARK PHARMA: CO TARGETING DOUBLE-DIGIT PAT MARGIN FOR THE FULL YEAR FY 25 - CONCALL UPDATE

NATCO PHARMA: Q4 EBITDA 4.97B RUPEES VS 3.4B (YOY) -- Q4 EBITDA MARGIN 46.55% VS 37.77% (YOY)

NATCO PHARMA: Q4 REVENUE 10.68B RUPEES VS 8.98B (YOY)

NATCO PHARMA: Q4 CONS NET PROFIT 3.86B RUPEES VS 2.76B (YOY)

ASTRAZENECA PHARMA: CO RECOMMENDED DIVIDEND OF 24 RUPEES PER EQUITY SHARE

ASTRAZENECA PHARMA: Q4 EBITDA 494M RUPEES VS 601.5M (YOY) -- Q4 EBITDA MARGIN 12.89% VS 21.13% (YOY)

ASTRAZENECA PHARMA: Q4 REVENUE 3.83B RUPEES VS 2.8B (YOY)

ASTRAZENECA PHARMA: Q4 SL NET PROFIT 394.8M RUPEES VS 173M (YOY)

SIGACHI INDUSTRIES: Q4 EBITDA 163M RUPEES VS 122M (YOY)

SIGACHI INDUSTRIES: Q4 REVENUE 1.04B RUPEES VS 724M (YOY)

SIGACHI INDUSTRIES: Q4 CONS NET PROFIT 150M RUPEES VS 73M (YOY)

GLAND PHARMA LTD: RS. 74.95 CRORES NSE BLOCK TRADE; FOR ~ 402073 SHARES, AT RS. 1864.15

TORRENT PHARMA: CO SAYS GUIDANCE FOR MARGIN IMPROVEMENT IS 50-100 BASIS POINTS - CONCALL UPDATE

TORRENT PHARMA: CO EXPECTS INDIA BUSINESS TO CONTINUE OUTPERFORMING MARKET GROWTH IN COMING QUARTERS -- CO EXPECTS TO GROW 2-3% HIGHER THAN MARKET GROWTH RATE OF 9% IN FY24 - CONCALL UPDATE

YATHARTH HOSPITAL: COS FOCUS ON EXPANDING IN TIER 2 AND TIER 3 CITIES IS EXPECTED TO DRIVE GROWTH - CONCALL UPDATE

DIVIS LAB: COS MANAGEMENT TEAM STATED THAT THEY ARE CONFIDENT IN THE COS ABILITY TO DELIVER STRONG FINANCIAL PERFORMANCE IN THE COMING YEAR, DRIVEN BY GROWTH IN ITS CORE BUSINESSES AND THE BENEFITS OF RECENT ACQUISITIONS - CONCALL UPDATE

SPARC: Q4 REVENUE 165.6M RUPEES VS 477M (YOY)

SPARC: Q4 SL NET LOSS 1.07B RUPEES VS LOSS 820M (YOY)

GLENMARK PHARMA: CO HAS EXCEPTIONAL ITEM OF 4.47B RUPEES

GLENMARK PHARMA: CO RECOMMENDED DIVIDEND OF 2.5 RUPEES PER SHARE

GLENMARK PHARMA: Q4 EBITDA 5.04B RUPEES VS 3.98B (YOY) -- Q4 EBITDA MARGIN 16.47% VS 13.26% (YOY)

GLENMARK PHARMA: Q4 REVENUE 30.63B RUPEES VS 30B (YOY)

GLENMARK PHARMA: Q4 CONS NET LOSS 12.2B RUPEES VS LOSS 4.3B (YOY)

BHAGIRADHA CHEMICALS: Q4 SL NET PROFIT 81.2M RUPEES VS 98M (YOY)

BAJAJ HEALTHCARE: CO HAS EXCEPTIONAL ITEM OF 443.3M RUPEES

BAJAJ HEALTHCARE: CO HAS RECOMMENDED FINAL DIVIDEND OF 1 RUPEE PER EQUITY SHARE

BAJAJ HEALTHCARE: Q4 EBITDA 160.3M RUPEES VS 220.2M (YOY) -- Q4 EBITDA MARGIN 11.97% VS 14.29% (YOY)

BAJAJ HEALTHCARE: Q4 REVENUE 1.34B RUPEES VS 1.54B (YOY)

BAJAJ HEALTHCARE: Q4 SL NET LOSS 299.2M RUPEES VS PROFIT 36M (YOY)

TORRENT PHARMACEUTICALS: CO RECOMMENDED TO MEMBERS TO OBTAIN APPROVAL FOR ISSUANCE OF EQUITY SHARES INCLUDING CONVERTIBLE BONDS / DEBENTURES -- CO SAYS ISSUANCE OF EQUITY SHARES INCLUDING CONVERTIBLE BONDS / DEBENTURES UP TO 50B RUPEES

TORRENT PHARMACEUTICALS: CO PROPOSED A FINAL EQUITY DIVIDEND OF 6 RUPEES PER EQUITY SHARE

TORRENT PHARMACEUTICALS: Q4 EBITDA 8.83B RUPEES VS 7.27B (YOY) -- Q4 EBITDA MARGIN 32.17% VS 29.19% (YOY)

TORRENT PHARMACEUTICALS: Q4 REVENUE 27.45B RUPEES VS 24.91B (YOY)

TORRENT PHARMACEUTICALS: Q4 CONS NET PROFIT 4.49B RUPEES VS 2.87B (YOY)

NARAYANA HRUDAYALAYA: CO BOARD RESOLVED TO SEEK ENABLING APPROVAL FROM SHAREHOLDERS FOR ISSUING DEBT SECURITIES FOR 12B RUPEES IN A FINANCIAL YEAR

NARAYANA HRUDAYALAYA: CO HAS RECOMMENDED FINAL DIVIDEND OF 4 RUPEES PER SHARE

NARAYANA HRUDAYALAYA: Q4 EBITDA 2.95B RUPEES VS 2.76B (YOY) -- Q4 EBITDA MARGIN 23.02% VS 22.57% (YOY)

NARAYANA HRUDAYALAYA: Q4 REVENUE 12.8B RUPEES VS 12.21B (YOY)

NARAYANA HRUDAYALAYA: Q4 CONS NET PROFIT 1.91B RUPEES VS 1.73B (YOY)

JIO FINANCIAL: CO PLANS RUPEES 36,000-CR DEAL WITH RELIANCE RETAIL - MC

GLAND PHARMA: USFDA INSPECTION CONCLUDED AT VISAKHAPATNAM FACILITY WITH ZERO OBSERVATION

ERIS LIFESCIENCES LTD: Rs. 20.10 Crores NSE Block Trade; for ~ 228456 Shares, at Rs. 880.00

APOLLO HOSPITALS ENTERPRISE LTD: Rs. 20.88 Crores NSE Block Trade; for ~ 35409 Shares, at Rs. 5898.00

ZYDUS LIFESCIENCES: CO ANNOUNCES COMPLETION OF ENROLMENT FOR PHASE II CLINICAL TRIAL OF USNOFLAST

SUN PHARMACEUTICAL INDUSTRIES LTD: Rs. 45.06 Crores NSE Block Trade; for ~ 303806 Shares, at Rs. 1483.25

CAPLIN POINT LABS: CAPLIN STERILES GETS USFDA APPROVAL FOR PHENYLEPHRINE HYDROCHLORIDE OPHTHALMIC SOLUTION USP -- THIS SOLUTIONS HAS US SALES OF USD 32M (CORRECTION)

CAPLIN POINT LABS: CAPLIN STERILES GETS USFDA APPROVAL FOR PHENYLEPHRINE HYDROCHLORIDE OPHTHALMIC SOLUTION USP -- THIS COLUTIONS HAS US SALES OF USD 32M

ZYDUS LIFESCIENCES LTD: Rs. 32.75 Crores NSE Block Trade; for ~ 301930 Shares, at Rs. 1084.85

MANKIND PHARMA: CO SAYS WILL LOOK AT ACQUISITIONS WHICH HAVE ENTRY BARRIERS - CNBC TV 18

BIOCON: CO SAYS LIRAGLUTIDE IS AN INJECTION IN PRE-FILLED PEN, USED IN THE TREATMENT OF CHRONIC WEIGHT MANAGEMENT AS AN ADJUNCT TO A REDUCED-CALORIE DIET AND INCREASED PHYSICAL ACTIVITY

BIOCON: CO SIGNS EXCLUSIVE LICENSING AND SUPPLY DEAL FOR THE COMMERCIALIZATION OF LIRAGLUTIDE IN SOUTH KOREA WITH HANDOK INC

MAX HEALTHCARE: CO SAYS THE 329-BED HOSPITAL AT NANAVATI IS ON SCHEDULE AND EXPECTED TO BE COMPLETED BY Q4 FY 25 - CONCALL UPDATE

JAGSONPAL PHARMA: CO LAUNCHES MEMUP: INDIAS FIRST BIOIDENTICAL HORMONE REPLACEMENT THERAPY IN A SINGLE PILL

MAX HEALTHCARE: CO AIMS TO PAY A MAXIMUM OF 20% TO 25% PRE-TAX ROCE FOR AN ASSET -- CO EXPECTS TO ACHIEVE A 20% TO 25% PRE-TAX ROCE WITHIN FOUR TO FIVE YEARS - CONCALL UPDATE

MAX HEALTHCARE: GUIDANCE FOR UTTAR PRADESH HOSPITALS: INFRASTRUCTURE REVAMP, BED CAPACITY EXPANSION, CLINICAL TALENT STRENGTHENING, AND ROBUST SALES PROGRAM TO DRIVE FUTURE GROWTH - CONCALL UPDATE

FORTIS HEALTHCARE: CO HAS EXCEPTIONAL ITEM OF 31.4M RUPEES

FORTIS HEALTHCARE: CO RECOMMENDED FINAL DIVIDEND OF 1 RUPEE PER EQUITY SHARE

FORTIS HEALTHCARE: Q4 EBITDA 3.85B RUPEES VS 2.7B (YOY) -- Q4 EBITDA MARGIN 21.58% VS 16.59% (YOY)

FORTIS HEALTHCARE: Q4 REVENUE 17.86B RUPEES VS 16.4B (YOY)

FORTIS HEALTHCARE: Q4 CONS NET PROFIT 2.03B RUPEES VS 1.4B (YOY)

SHILPA MEDICARE: CO HAS EXCEPTIONAL ITEM OF LOSS 61.3M RUPEES

SHILPA MEDICARE: Q4 EBITDA 699.2M RUPEES VS 370.2M (YOY) -- Q4 EBITDA MARGIN 23.97% VS 14.05% (YOY)

SHILPA MEDICARE: Q4 REVENUE 2.92B RUPEES VS 2.64B (YOY)

SHILPA MEDICARE: Q4 CONS NET PROFIT 245M RUPEES VS LOSS 81M (YOY)

SUN PHARMA: CO SAYS MERGER AGREEMENT BETWEEN TARO PHARMACEUTICAL INDUSTRIES AND CO IS APPROVED BY AFFIRMATIVE VOTE OF TARO SHAREHOLDERS -- COMPLETION OF MERGER BETWEEN TARO PHARMACEUTICAL INDUSTRIES AND CO EXPECTED TO CLOSE IN ABOUT 35 DAYS

CONCORD BIOTECH: CO APPROVED DIVIDEND OF 8.75 RUPEES PER SHARE

CONCORD BIOTECH: Q4 EBITDA 1.34B RUPEES VS 1.29B (YOY)

CONCORD BIOTECH: Q4 REVENUE 3.2B RUPEES VS 2.73B (YOY)

CONCORD BIOTECH: Q4 SL NET PROFIT 972M RUPEES VS 935M (YOY)

SUN PHARMA: RS 91.72CR NSE BLOCK TRADE; FOR ~620617 SHARES, AT RS 1477.95

PIRAMAL PHARMA: CO SAYS US FDA HAS ISSUED AN ESTABLISHMENT INSPECTION REPORT (EIR) FOR COS MANUFACTURING FACILITY LOCATED AT LEXINGTON, USA

MOREPEN LAB: CO EXPECTS ITS EBITDA MARGINS TO INCREASE TO 18%-19% OVER THE NEXT FIVE YEARS, DRIVEN BY THE GROWTH IN ITS DEVICES BUSINESS - CONCALL UPDATE

SUN PHARMA: CO IS ON TRACK TO LAUNCH A NEW PRODUCT POST THE PDUFA DATE - CONCALL UPDATE

SUN PHARMA: CO SAYS GUIDANCE FOR FY 25: HIGH SINGLE-DIGIT CONSOLIDATED TOP-LINE GROWTH - CONCALL UPDATE

STRIDES PHARMA: CO IS GROWING AT A 15% CAGR AND AIMS TO REACH 21% EBITDA AND BE DEBT-FREE IN 3 YEARS - CONCALL UPDATE

GLAND PHARMA: CO RECOMMENDS A FINAL DIVIDEND OF 20 RUPEES PER EQUITY SHARE

GLAND PHARMA: Q4 EBITDA 3.59B RUPEES VS 1.68B (YOY) -- Q4 EBITDA MARGIN 23.33% VS 21.54% (YOY)

GLAND PHARMA: Q4 REVENUE 15.37B RUPEES VS 7.85B (YOY)

GLAND PHARMA: Q4 CONS NET PROFIT 1.92B RUPEES VS 786.8M (YOY)

SUN PHARMA: CO APPROVED DIVIDEND OF 5 RUPEES PER SHARE

SUN PHARMA INDUSTRIES: Q4 EBITDA 30.35B RUPEES VS 28.02B (YOY); EST 30.32B -- Q4 EBITDA MARGIN 25.33% VS 25.64% (YOY); EST 24.6%

SUN PHARMA: CO HAS Q4 ONE-TIME LOSS OF 1.02B RUPEES

SUN PHARMA INDUSTRIES: Q4 REVENUE 119.8B RUPEES VS 109B (YOY); EST 123.17B

MAX HEALTHCARE INSTITUTE: CO APPROVED OVERALL SPEND OF UPTO 3.76B RUPEES TOWARD EXPANSION OF MOHALI HOSPITAL

SUN PHARMA INDUSTRIES: Q4 CONS NET PROFIT 26.5B RUPEES VS 19.8B (YOY); EST 23.77B

MAX HEALTHCARE INSTITUTE: Q4 EBITDA 3.8B RUPEES VS 3.4B (YOY)

MAX HEALTHCARE INSTITUTE : Q4 REVENUE 14.2B RUPEES VS 12B (YOY)

MAX HEALTHCARE INSTITUTE : Q4 CONS NET PROFIT 2.52B RUPEES VS 2.5B (YOY)

STRIDES PHARMA: CO IS AIMING FOR AN EBITDA FOR FY25 OF RUPEES 10B VS CURRENT YEAR IS 7.5B RUPEES

STRIDES PHARMA: CO AIM TO ACHIEVE $400M IN THE NEXT 3 YEARS

STRIDES PHARMA SCIENCE: CO SAYS SIGNIFICANT GROWTH TO COME IN H2 FY25 BASED ON TARGETED PRODUCT LAUNCHES GLOBALLY

STRIDES PHARMA: CO SAYS SIGNIFICANT GROWTH TO COME IN H2FY25 BASED ON TARGETED PRODUCT LAUNCHES GLOBALLY

STRIDES PHARMA: CO SAYS EBITDA MARGIN TO BE IN THE RANGE OF 20%- 22%

STRIDES PHARMA SCIENCE: CO AIMING FOR NET DEBT REDUCTION OF RUPEES 5,000M (INCLUDING DEBT PUSHDOWN OF RUPEES 2,800M TO ONESOURCE )

STRIDES PHARMA SCIENCE: CO SEES CONTINUING BUSINESS REVENUE TO GROW AT 12-15% YOY FOR FY25

STRIDES PHARMA SCIENCE: Q4 EBITDA 2.29B RUPEES VS 1.6B (YOY) -- Q4 EBITDA MARGIN 21.19% VS 15.77% (YOY)

STRIDES PHARMA SCIENCE: Q4 REVENUE 10.8B RUPEES VS 9.8B (YOY)

STRIDES PHARMA SCIENCE: Q4 CONS NET PROFIT 181M RUPEES VS LOSS 95M (YOY)

ZYDUS LIFE: CO RECEIVES FINAL APPROVAL FROM USFDA FOR THEOPHYLLINE EXTENDED-RELEASE TABLETS, 300 MG AND 450 MG

AUROBINDO PHARMA LTD: Rs. 46.32 Crores NSE Block Trade; for ~ 381259 Shares, at Rs. 1215.05

METROPOLIS HEALTH: CO DELIVERED 13.3% YEAR-OVER-YEAR GROWTH IN THE LAST YEAR AND IS LOOKING TO TAKE THIS FURTHER BEYOND THIS NUMBER, WITH A MID-TEEN KIND OF GROWTH EXPECTED IN FY 25 -- GUIDANCE WOULD BE 13-15% - CONCALL UPDATES

METROPOLIS HEALTH: CO DELIVERED 13.3% YEAR-OVER-YEAR GROWTH IN THE LAST YEAR AND IS LOOKING TO TAKE THIS FURTHER BEYOND THIS NUMBER, WITH A MID-TEEN KIND OF GROWTH EXPECTED IN FY 25 - CONCALL UPDATE

METROPOLIS HEALTH: CO SAYS GUIDANCE FOR FY 25 IS FOR EBITDA MARGINS OF 25.5% TO 26%, WHICH INCLUDES DILUTION FROM THE NEW LAB - CONCALL UPDATE

CIPLA: CO RECEIVES FINAL APPROVAL FOR THE GENERIC VERSION OF SOMATULINE DEPOT (LANREOTIDE) INJECTION -- IT HAS US SALES OF USD 898M

STRIDES PHARMA: SUCRALFATE ORAL SUSPENSION HAS US SALES OF USD 124M

STRIDES PHARMA: CO RECEIVES USFDA APPROVAL FOR SUCRALFATE ORAL SUSPENSION

GRANULES INDIA LTD: RS. 82.03 CRORES NSE BLOCK TRADE; FOR ~ 2025000 SHARES, AT RS. 405.10 (PRE OPEN BLOCK)

ERIS LIFE: CO SAYS GUIDANCE FOR FY 25 DOMESTIC FORMULATIONS ORGANIC GROWTH IS 12% TO 15% - CONCALL UPDATES

JB CHEMICALS & PHARMA: CO TO LAUNCH NEW PRODUCTS STARTING IN OCTOBER, AIMING TO BOOST GROWTH IN SECOND HALF OF THE YEAR - CONCALL UPDATE

JB CHEMICALS & PHARMA: CO SAYS BOTH INDIA AND CDMO WILL CONTRIBUTE OVERALL TO THE GROWTH OF THE COMPANY AND, OVERALL, GENERATING GROSS MARGINS CLOSE TO 65% FOR THE COMING 2 YEARS - CONCALL UPDATE

METROPOLIS HEALTHCARE: Q4 EBITDA 799.8M RUPEES VS 703M (YOY) -- Q4 EBITDA MARGIN 24.16% VS 24.88% (YOY)

METROPOLIS HEALTHCARE: Q4 REVENUE 3.31B RUPEES VS 2.83B (YOY)

METROPOLIS HEALTHCARE: Q4 CONS NET PROFIT 364.1M RUPEES VS 333.4M (YOY)

ASTRAZENECA PHARMA INDIA: CO RECEIVED PERMISSION FOR VOLUNTARY WITHDRAWAL OF INDICATION OF OLAPARIB (LYNPARZA) -- INDICATION FOR TREATMENT OF PATIENT WITH GBRCA MUTATION AND ADVANCED OVARIAN CANCER

BIOCON: BIOCON BIOLOGICS OBTAINS U.S. FDA APPROVAL FOR BIOSIMILAR AFLIBERCEPT FOR YESAFILI™. ENTERS U.S. OPHTHALMOLOGY MARKET -- SECURED A LAUNCH DATE IN CANADA OF NO LATER THAN JULY 1, 2025, UNDER TERMS OF A SETTLEMENT AGREEMENT

INDOCO REMEDIES: CO RECEIVES FINAL ANDA APPROVAL FROM USFDA FOR PREGABALIN CAPSULES -- PREGABALIN CAPSULES WILL BE MANUFACTURED BY CO AT GOA

ERIS LIFESCIENCES: CO APPROVED ISSUANCE OF NON-CONVERTIBLE DEBENTURES WORTH UPTO 12.50 BLN RUPEES THROUGH PRIVATE PLACEMENT

ERIS LIFESCIENCES: Q4 EBITDA 1.48B RUPEES VS 1.2B (YOY) -- Q4 EBITDA MARGIN 26.94% VS 29.52% (YOY)

ERIS LIFESCIENCES: Q4 REVENUE 5.51B RUPEES VS 4B (YOY)

ERIS LIFESCIENCES: Q4 CONS NET PROFIT 709.6M RUPEES VS 654M (YOY)

WOCKHARDT: BOARD MEETING ON 28 MAY TO CONSIDER Q4 RESULTS -- CO TO CONSIDER RAISING OF FUNDS

DR REDDYS LABORATORIES: DR. REDDY’S SWISS TO OBTAIN EXCLUSIVE RIGHTS FOR US MARKET, SEMI-EXCLUSIVE RIGHTS FOR EUROPE MARKETS FOR $38 MLN -- CERTAIN SUCCESS BASED COMMERCIAL MILESTONES PAYMENT UPTO $29 MLN, PAYABLE TO ALVOTECH AS PART OF DEAL

DR REDDYS LABORATORIES: ALVOTECH AND DR. REDDY’S ENTER INTO COLLABORATION FOR COMMERCIALIZATION OF AVT03 (DENOSUMAB), A BIOSIMILAR CANDIDATE TO PROLIA® & XGEVA® IN THE U.S., EUROPE AND UK

MOREPEN LABORATORIES: Q4 EBITDA 483.8M RUPEES VS 155.6M (YOY) -- Q4 EBITDA MARGIN 11.44% VS 4.28% (YOY)

MOREPEN LABORATORIES: Q4 REVENUE 4.23B RUPEES VS 3.64B (YOY)

MOREPEN LABORATORIES: Q4 CONS NET 287.4M PROFIT RUPEES VS 82.4M (YOY)

JB PHARMA: CO SAYS DOMESTIC BIZ WILL BE 60% OF REVENUE VS 53% RIGHT NOW IN COUPLE OF YEARS - CNBC TV 18

JB PHARMA: CO EXEC SAYS TARGET 26 -28% EBITDA MARGIN GOING FORWARD - CNBC TV18

JB PHARMA: CO WILL SEE MID TERM GROWTH IN LOZENGES BUSINESS IN H2FY25 - CNBCTV 18

CIPLA LTD: Rs. 32.78 Crores NSE Block Trade; for ~ 231074 Shares, at Rs. 1418.80

GLOBAL HEALTH: Rs 31.59cr NSE Block Trade; for ~234446 shares, at Rs 1347.5

BIOCON: COS BIOLOGICS OBTAINS USFDA APPROVAL FOR BIOSIMILAR AFLIBERCEPT FOR YESAFILI ENTERS U.S. OPHTHALMOLOGY MARKET

GLENMARK PHARMA: CO AND BEIGENE ENTER INTO AN AGREEMENT FOR MARKETING AND DISTRIBUTION OF TISLELIZUMAB AND ZANUBRUTINIB IN INDIA

POLY MEDICURE: CO IS GUIDING FOR ALMOST 50% INCREASE IN RENAL BUSINESS -- CO FURTHER SAYS GUIDANCE FOR THIS YEAR IS 22% TO 25% GROWTH - CONCALL UPDATES

PFIZER: CO RECOMMENDED A DIVIDEND OF 35 RUPEES PER EQUITY SHARE

PFIZER: Q4 EBITDA 1.89B RUPEES VS 1.82B (YOY) -- Q4 EBITDA MARGIN 34.65% VS 31.76% (YOY)

PFIZER: Q4 REVENUE 5.47B RUPEES VS 5.73B (YOY)

PFIZER: Q4 SL NET PROFIT 1.79B RUPEES VS 1.3B (YOY)

J.B.CHEMICALS & PHARMA: CO RECOMMENDED A FINAL DIVIDEND OF 6.75 RUPEES PER EQUITY SHARE

J.B.CHEMICALS & PHARMA: Q4 EBITDA 1.98B RUPEES VS 1.64B (YOY) -- Q4 EBITDA MARGIN 22.99% VS 21.47% (YOY)

J.B.CHEMICALS & PHARMA: Q4 REVENUE 8.62B RUPEES VS 7.62B (YOY)

J.B.CHEMICALS & PHARMA: Q4 CONS NET PROFIT 1.26B RUPEES VS 876M (YOY)

DR REDDYS LAB: CO SAYS USFDA COMPLETED A ROUTINE GMP INSPECTION AT OUR FORMULATIONS MANUFACTURING FACILITIES IN DUVVADA -- CO SAYS HAVE BEEN ISSUED A FORM 483 WITH TWO OBSERVATIONS

ZYDUS LIFESCIENCES: CO HAS RECOMMENDED FINAL DIVIDEND OF 3 RUPEES PER EQUITY SHARE

ZYDUS LIFESCIENCES: Q4 EBITDA 16.3B RUPEES VS 12.56B (YOY); EST 15.85B -- Q4 EBITDA MARGIN 29.46% VS 25.06% (YOY); EST 29.8%

ZYDUS LIFESCIENCES: Q4 CONS NET PROFIT 11.82B RUPEES VS 2.97B (YOY); EST 10.28B -- Q4 REVENUE 55.34B RUPEES VS 50.1B (YOY); EST 53.18B

GLOBAL HEALTH: Q4 EBITDA 1.79B RUPEES VS 1.67B (YOY) -- Q4 EBITDA MARGIN 22.18% VS 23.58% (YOY)

GLOBAL HEALTH: Q4 CONS NET PROFIT 1.27B RUPEES VS 1.01B (YOY) -- Q4 REVENUE 8.09B RUPEES VS 7.07B (YOY)

CONCORD BIOTECH: CO SAYS SAUDI FOOD AND DRUG AUTHORITY HAS SUCCESSFULLY COMPLETED INSPECTION OF CO UNIT IN GUJARAT

INDRAPRASTHA MEDICAL CORP: Q4 EBITDA 484M RUPEES VS 331M (YOY) -- Q4 EBITDA MARGIN 15.39% VS 12.07% (YOY)

INDRAPRASTHA MEDICAL CORP: Q4 REVENUE 3.14B RUPEES VS 2.74B (YOY)

INDRAPRASTHA MEDICAL CORP: Q4 SL NET PROFIT 310M RUPEES VS 198M (YOY)

GLAXOSMITHKLINE PHARMA: Q4 EBITDA 2.57B RUPEES VS 1.7B (YOY) -- Q4 EBITDA MARGIN 27.67% VS 21.56% (YOY)

GLAXOSMITHKLINE PHARMA: CO APPROVED DIVIDEND OF 32 RUPEES PER SHARE

GLAXOSMITHKLINE PHARMA: Q4 REVENUE 9.3B RUPEES VS 7.9B (YOY)

GLAXOSMITHKLINE PHARMA: Q4 CONS NET PROFIT 2B RUPEES VS 1.3B (YOY)

POLY MEDICURE : Q4 EBITDA 966M RUPEES VS 832M (YOY)

POLY MEDICURE : Q4 REVENUE 3.7B RUPEES VS 3.3B (YOY)

POLY MEDICURE : Q4 CONS NET PROFIT 684M RUPEES VS 588M (YOY)

GLENMARK PHARMA: CO RECEIVES ANDA APPROVAL FOR BRIMONIDINE TARTRATE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION -- CO SAYS SOLUTION HAS U.S SALES OF 290M USD

ZYDUS LIFESCIENCES: CO SAYS THE TOTAL ADDRESSABLE MARKET OPPORTUNITY OF CABOZANTINIB TABLETS IN US IS APPROXIMATELY USD 1,464 M

ZYDUS LIFESCIENCES: CO AND MSN ANNOUNCES EXCLUSIVE LICENSING AND SUPPLY AGREEMENT FOR CABOZANTINIB TABLETS FOR THE US MARKET

BIOCON: CO MADE FILINGS FOR 38 DRUG PRODUCTS AND 37 APIS AND RECEIVED APPROVALS FOR 24 PRODUCTS AND 20 APIS ACROSS GLOBAL MARKETS - CONCALL UPDATE

BIOCON: CO SAYS DESPITE PRICING PRESSURES IN THE API BUSINESS, THE FORMULATIONS BUSINESS GREW 36% (YOY) - CONCALL UPDATE

BIOCON: CO ACQUIRED AN ORAL SOLID DOSAGE US MANUFACTURING FACILITY LOCATED IN NEW JERSEY -- CO SAYS FACILITY EXPECTED TO BEGIN COMMERCIAL OPERATIONS IN FISCAL25 SUBJECT TO REGULATORY CLEARANCE - CONCALL UPDATE

IOLCP: COS GUIDANCE FOR NEXT YEAR IS 10% TO 12% UPSIDE IN REVENUE -- EBITDA IS EXPECTED TO INCREASE BETWEEN 12% TO 15% IN THE FINANCIAL YEAR 25 - EARNINGS CONCALL

BIOCON: CO EXPECTS LIRAGLUTIDE TO MEANINGFULLY START CONTRIBUTING TO GROWTH FROM FY26

BIOCON: COS GUIDANCE FOR FISCAL 25 INCLUDES REVENUE GROWTH AT SINGLE-DIGIT TO LOW DOUBLE-DIGITS ON A CONSTANT CURRENCY BASIS - CONCALL UPDATE

MANKIND PHARMA: CO EXPECTS TO INCREASE ITS FIELD FORCE BY 700 TO 900 PEOPLE THIS YEAR, WHICH WILL HELP DRIVE GROWTH - EARNINGS CONCALL

MANKIND PHARMA: CO SAYS HE LEVERS FOR THE IMPROVED MARGIN GUIDANCE ARE HIGHER CHRONIC, WHICH HAS ALREADY SEEN A 160 BASIS POINT IMPROVEMENT (YOY), AND AN INCREASE IN THE NUMBER OF RUPEES 100 CR AND RUPEES 50 CR BRANDS

MANKIND PHARMA: COS GUIDANCE FOR THE YEAR IS FOR REVENUE GROWTH OF 4% TO 5% MARGIN GUIDANCE IS 25% TO 26%, WHICH IS ONE NOTCH ABOVE THE PREVIOUS GUIDANCE OF 24% TO 26% - EARNINGS CONCALL

MANKIND PHARMA: COS GUIDANCE FOR FY 25 EBITDA MARGIN IS 25% TO 26%. GUIDANCE FOR NEW PRODUCT CONTRIBUTION TO GROWTH IS 3.5% TO 4% - EARNINGS CONCALL

SEQUENT SCIENTIFIC: COS GUIDANCE FOR NEXT YEAR IS FOR EBITDA MARGINS TO BE IN THE LOW TO MID-TEEN RANGE - EARNINGS CONCALL

SEQUENT SCIENTIFIC: CO EXPECTS REVENUE GROWTH TO BE IN THE LOW TO MID-TEENS - EARNINGS CONCALL

SEQUENT SCIENTIFIC: CO SAYS THE INDIA BUSINESS IS EXPECTED TO GROW AT A DOUBLE-DIGIT RATE - EARNINGS CONCALL

KRISHNA INSTITUTE OF MEDICAL SCIENCES: CO SAYS NASHIK UNIT COMING UP IN Q1FY25, THANE AND BANGALORE UNITS GETTING OPERATIONALIZED BY END OF FY25

BIOCON: CO SAYS FOCUS IN FY25 WILL BE DIRECTED TOWARDS LAUNCHING NEW PRODUCTS AND EXPANDING OUR GEOGRAPHIC REACH-- CO SAYS WILL CONTINUE TO FOCUS ON MULTIPLE COST IMPROVEMENT INITIATIVES -- CO SAYS INTEND TO BUILD UPON OUR INITIAL REGULATORY SUCCESS IN OUR PEPTIDE AND GLP-1 FOCUSED PIPELINE IN STRATEGIC MARKETS

KRISHNA INSTITUTE OF MEDICAL SCIENCES: Q4 EBITDA 1.59B RUPEES VS 1.63B (YOY) -- Q4 EBITDA MARGIN 25.1% VS 28.34% (YOY)

KRISHNA INSTITUTE OF MEDICAL SCIENCES: Q4 CONS NET PROFIT 655M RUPEES VS 933M (YOY) -- Q4 REVENUE 6.34B RUPEES VS 5.76B (YOY)

BIOCON: Q4 EBITDA 9.16B RUPEES VS 9.97B (YOY); EST 8.26B -- Q4 EBITDA MARGIN 23.38% VS 26.43% (YOY); EST 21.5%

BIOCON: Q4 CONS NET PROFIT 1.35B RUPEES VS 3.13B (YOY); EST 1.79B -- Q4 REVENUE 39.2B RUPEES VS 37.74B (YOY); EST 38.41B

JAGSONPAL PHARMA: DEAL FOR 924.7M RUPEES; ACQUISITION IS A GATEWAY TO DERMATOLOGY AND CHILDCARE SEGMENTS -- CO HAD CASH BALANCE OF 1.35B RUPEES AS ON DECEMBER 31, 2023

JAGSONPAL PHARMA: CO SAYS SIGNED BUSINESS TRANSFER AGREEMENT FOR PURCHASE OF INDIA, BHUTAN BUSINESS OF YASH PHARMA

MAX HEALTHCARE INSTITUTE: BOARD MEETING ON MAY 22 TO CONSIDER Q4 RESULTS -- CO TO RECOMMEND FINAL DIVIDEND, IF ANY

INDOCO REMEDIES: CO SAYS COMPLETION OF INSPECTION COS API KILO LAB MANUFACTURING FACILITY AND INDOCO ANALYTICAL SOLUTIONS DIVISION -- INSPECTION WAS CONCLUDED WITH ZERO FORM 483 OBSERVATIONS

ARTEMIS: CO COMPLETES THE FUND RAISE OF RS 3,300 MILLION FROM IFC TO SUPPORT ITS EXPANSION PLANS AND BOLSTER ITS HEALTHCARE FOOTPRINT

INDOCO REMEDIES: Q4 REVENUE 4.4B RUPEES VS 4.3B (YOY)

INDOCO REMEDIES: Q4 EBITDA 488M RUPEES VS 648M (YOY) -- Q4 EBITDA MARGIN 10.87% VS 15.13% (YOY)

INDOCO REMEDIES: Q4 CONS PROFIT BEFORE EXCEPTIONAL132M RUPEES VS 389M (YOY)

CAPLIN POINT LAB: Q4 EBITDA 1.45B RUPEES VS 1.24B (YOY) -- Q4 EBITDA MARGIN 32.04% VS 31.84% (YOY)

CAPLIN POINT LAB: Q4 REVENUE 4.5B RUPEES VS 3.9B (YOY)

CAPLIN POINT LAB: Q4 CONS NET PROFIT 1.2B RUPEES VS 1B (YOY)

KOPRAN: CO RECOMMENDED DIVIDEND OF RS. 3.00 PER EQUITY SHARE

KOPRAN: Q4 EBITDA 244M RUPEES VS 144M (YOY) -- Q4 EBITDA MARGIN 13.11% VS 9.67% (YOY)

KOPRAN: Q4 REVENUE 1.86B RUPEES VS 1.48B (YOY)

KOPRAN: Q4 CONS NET 186M PROFIT RUPEES VS 80M (YOY)

LINCOLN PHARMA:CO RECOMMENDED A DIVIDEND OF 1.80 RS PER SHARE

LINCOLN PHARMA: Q4 EBITDA 184M RUPEES VS 166M (YOY)

LINCOLN PHARMA: Q4 REVENUE 1.4B RUPEES VS 1.1B (YOY)

LINCOLN PHARMA: Q4 sl NET PROFIT 186M RUPEES VS 126M (YOY)

SEQUENT SCIENTIFIC: CO HAS EXCEPTIONAL ITEM OF LOSS 47.1M RUPEES

SEQUENT SCIENTIFIC: Q4 EBITDA PROFIT 322.7M RUPEES VS LOSS 33.7M (YOY) -- Q4 EBITDA MARGIN 8.93% VS -0.92% (YOY)

SEQUENT SCIENTIFIC: Q4 CONS NET LOSS 9.11M RUPEES VS LOSS 936M (YOY) -- Q4 REVENUE 3.6B RUPEES VS 3.67B (YOY)

MANKIND PHARMA: CO SAYS RAISING OF FUNDS FOR UPTO 75B RUPEES --RAISING OF FUNDS VIA ISSUANCE OF SHARES

MANKIND PHARMA: Q4 EBITDA 5.91B RUPEES VS 4.17B (YOY); EST 5.52B -- Q4 EBITDA MARGIN 24.21% VS 20.30% (YOY); EST 22.5%

MANKIND PHARMA: Q4 CONS NET PROFIT 4.7B RUPEES VS 2.85B (YOY); EST 3.96B -- Q4 REVENUE 24.4B RUPEES VS 20.53B (YOY); EST 24.68B

CIPLA: CO SIGNED DEFINITIVE AGREEMENTS FOR FURTHER INVESTMENT OF UP TO 260M RUPEES IN OPTIONALLY CONVERTIBLE PREFERENCE SHARES OF ACHIRA LABS -- PURSUANT TO COMPLETION OF FIRST TRANCHE OF INVESTMENT, CIPLA SHALL HOLD 27.27% OF TOTAL VOTING RIGHTS IN ACHIRA

LUPIN: CO SAYS ALL 12 OF COS MANUFACTURING SITES COMPLETED AUDITS AND CERTIFIED BY DNV FOR ISO 14001 AND ISO 45001

GRANULES: GRANULES LIFE SCIENCES (GLS), WITH PLANNED FD CAPACITY OF 8B DOSAGE, SUCCESSFULLY COMMENCED OPERATIONS IN MARCH 24 -- THE FACILITY TO ACHIEVE 2.5 BN DOSAGE RUN RATE BY MARCH 25

GRANULES INDIA: CO SAYS DECLINE IN PARA API SALES IN Q4 FY24 DUE TO HIGHER CUSTOMER INVENTORY, PRICE EROSION

GRANULES: CO MD SAYS WITH CONTINUED GROWTH IN FORMULATIONS SHARE COMING FROM US AND EUROPE AS PART OF OUR GLOBAL EXPANSION STRATEGY AND A HIGHER CONTRIBUTION FROM NEW PRODUCTS

GRANULES: Q4 EBITDA 2.5B RUPEES VS 2.2B (YOY) -- Q4 EBITDA MARGIN 21.75% VS 19.08% (YOY)

GRANULES: Q4 REVENUE 11.8b RUPEES VS 11.96B (YOY)

GRANULES: Q4 CONS NET PROFIT 1.3B RUPEES VS 1.2B (YOY)

CIPLA: RS 2648.2CR NSE BLOCK TRADE; FOR ~19689199 SHARES, AT RS 1345 (PRE-OPEN BLOCK)

NEULAND LAB: CO IS DEVELOPING A GLP-1 GENERIC FOR THE REGULATED MARKETS, WHICH COULD ALSO BE USED IN LOCAL MARKETS - CONCALL UPDATE

NEULAND LAB: CO SAYS FY25 IS EXPECTED TO HAVE MODEST GROWTH, WHILE FY26 AND FY27 ARE EXPECTED TO HAVE BETTER GROWTH - CONCALL UPDATE

THEMIS MEDICARE: CO HAS RECOMMENDED A DIVIDEND OF 0.50 RUPEES PER EQUITY SHARE

THEMIS MEDICARE: Q4 EBITDA 93M RUPEES VS 104.8M (YOY) -- Q4 EBITDA MARGIN 9.5% VS 13.08% (YOY)

THEMIS MEDICARE: Q4 CONS NET PROFIT 66.4M RUPEES VS 84.1M (YOY) -- Q4 REVENUE 978.2M RUPEES VS 801M (YOY)

SHILPA MEDICARE: CO ANNOUNCES SUCCESSFUL COMPLETION OF EARLY CLINICAL DEVELOPMENT AND ONGOING PHASE 3 CLINICAL TRIAL OF DRUG SML-007 -- PHASE 3 CLINICAL STUDY DOSING IS EXPECTED TO BE COMPLETED BY END OF Q1, STUDY IS LIKELY TO BE CONCLUDED BY Q2 END

IOL CHEM AND PHARMA: Q4 EBITDA 500.8M RUPEES VS 958M (YOY) -- Q4 EBITDA MARGIN 9.94% VS 16.31% (YOY)

IOL CHEM AND PHARMA: Q4 SL NET PROFIT 281.9M RUPEES VS 653M (YOY) -- Q4 REVENUE 5.04B RUPEES VS 5.9B (YOY)

THYROCARE TECHNOLOGIES: Q4 EBITDA 338M RUPEES VS 247M (YOY) -- Q4 EBITDA MARGIN 21.92% VS 18.17% (YOY)

THYROCARE TECHNOLOGIES: Q4 REVENUE 1.54B RUPEES VS 1.36B (YOY)

THYROCARE TECHNOLOGIES: Q4 CONS NET PROFIT 178M RUPEES VS 126M (YOY)

MANKIND PHARMA: ADVENT SEEKING A VALUATION OF ABOUT $2B FOR BHARAT SERUM - CNBC TV 18

MANKIND PHARMA: CO LOOKING TO ACQUIRE BHARAT SERUM AND VACCINES FROM PE CO ADVENT -- ADVENT HAS 100% OWNERSHIP OF BHARAT SERUM & VACCINES & NOW IS LOOKING TO EXIT - CNBC TV18

PIRAMAL PHARMA: CO SAYS GUIDANCE FOR FY 25: REVENUE AND ABSOLUTE EBITDA TO BE IN THE EARLY TEENS; GROWTH MOMENTUM IN CDMO BUSINESS TO CONTINUE - CONCALL UPDATES

JUPITER LIFE LINE: CO HAS A SHORT-TERM TARGET OF GETTING TO 2,500 BEDS AND HAS A 1000-BED VISIBILITY THAT TAKES THEM FROM 1,200 TO 2,200 BEDS - CONCALL UPDATES

SUN PHARMA: BOARD MEETING ON MAY 22 TO CONSIDER Q4 RESULTS -- CO TO RECOMMEND FINAL DIVIDEND, IF ANY

BIOCON: CO SIGNS SEMI-EXCLUSIVE DISTRIBUTION AND SUPPLY DEAL FOR THE COMMERCIALIZATION OF GENERIC SAXENDA® (LIRAGLUTIDE) IN MEXICO WITH MEDIX

PIRAMAL PHARMA: CO HAS EXCEPTIONAL ITEM OF LOSS 305.2M RUPEES

PIRAMAL PHARMA: CO HAS RECOMMENDED A FINAL DIVIDEND OF 0.11 RUPEES PER EQUITY SHARE

PIRAMAL PHARMA: Q4 EBITDA 5.3B RUPEES VS 3.51B (YOY) -- Q4 EBITDA MARGIN 20.76% VS 16.24% (YOY)

PIRAMAL PHARMA: Q4 CONS NET PROFIT 1.01B RUPEES VS 501M (YOY); 101.1M (QOQ) -- Q4 REVENUE 25.52B RUPEES VS 21.6B (YOY); 19.6B (QOQ)

AMI ORGANICS: CO HAS RECOMMENDED A FINAL DIVIDEND OF 3 RUPEES PER SHARE

AMI ORGANICS: Q4 EBITDA 401.5M RUPEES VS 408M (YOY) -- Q4 EBITDA MARGIN 18.26% VS 21.9% (YOY)

AMI ORGANICS: Q4 SL NET PROFIT 320.8M RUPEES VS 272M (YOY); 157M (QOQ) -- Q4 REVENUE 2.2B RUPEES VS 1.86B (YOY); 1.6B (QOQ)

JUPITER LIFE LINE HOSPITALS: CO APPROVED ADDITION OF 75 BEDS IN EXISTING INDORE HOSPITAL, 22 BEDS IN EXISTING PUNE HOSPITAL -- TOTAL PROJECT COST OF 180M RUPEES

JUPITER LIFE LINE HOSPITALS: CO HAS EXCEPTIONAL ITEM OF 22.8M RUPEES

JUPITER LIFE LINE HOSPITALS: CO HAS RECOMMENDED A FINAL DIVIDEND OF 1 RUPEE PER EQUITY SHARE

JUPITER LIFE LINE HOSPITALS: Q4 EBITDA 622.8M RUPEES VS 515.8M (YOY) -- Q4 EBITDA MARGIN 21.44% VS 21.29% (YOY)

JUPITER LIFE LINE HOSPITALS: Q4 CONS NET PROFIT 452.7M RUPEES VS 157.5M (YOY); 436.7M (QOQ) -- Q4 REVENUE 2.9B RUPEES VS 2.42B (YOY); 2.73B (QOQ)

NEULAND LABORATORIES: CO WILL CONTINUE TO INVEST FOR FUTURE BY ADDING CAPACITY AND CAPABILITIES

NEULAND LABORATORIES: CO RECOMMENDED FINAL DIVIDEND OF 14 RUPEES PER EQUITY SHARE

NEULAND LABORATORIES: Q4 EBITDA 1.07B RUPEES VS 1.2B (YOY) -- Q4 EBITDA MARGIN 27.74% VS 29.41% (YOY)

NEULAND LABORATORIES: Q4 SL NET PROFIT 676.1M RUPEES VS 845M (YOY); 807M (QOQ) -- Q4 REVENUE 3.85B RUPEES VS 4.1B (YOY); 3.93B (QOQ)

ARTEMIS MEDICARE: CO RECOMMENDED THE FINAL DIVIDEND OF 0.45 RUPEES PER EQUITY SHARE

ARTEMIS MEDICARE: Q4 EBITDA 361.1M RUPEES VS 245.3M (YOY) -- Q4 EBITDA MARGIN 16.65% VS 13.11% (YOY)

ARTEMIS MEDICARE: Q4 SL NET PROFIT 139.2M RUPEES VS 104M (YOY); 115M (QOQ) -- Q4 REVENUE 2.17B RUPEES VS 1.87B (YOY); 2.1B (QOQ)

GLENMARK PHARMA: CO ENTERED INTO SECURITIES SUBSCRIPTION & SHAREHOLDERS’ AGREEMENT WITH O2 RENEWABLE ENERGY XXIV, O2 ENERGY SG PTE -- ENTERED INTO POWER PURCHASE AGREEMENT WITH O2 RENEWABLE ENERGY XXIV; DEAL FOR 17.5M RUPEES

LUPIN: CO SAYS RE-LAUNCH OF MIRABEGRON EXTENDED-RELEASE (ER) TABLETS 25 MG IN UNITED STATES -- US COURT LIFTED TEMPORARY RESTRAINING ORDER, DENIED ASTELLAS REQUEST FOR PRELIMINARY INJUNCTION ON MIRABEGRON ER TABLETS -- SHIPMENT OF PRODUCT HAS NOW RESUMED

LUPIN: CO SAYS RE-LAUNCH OF MIRABEGRON EXTENDED-RELEASE (ER) TABLETS 25 MG IN UNITED STATES -- US COURT LIFTED TEMPORARY RESTRAINING ORDER, DENIED ASTELLAS REQUEST FOR PRELIMINARY INJUNCTION ON MIRABEGRON ER TABLETS

CIPLA: CIPLA GLOBAL CEO - WE WILL SEE NEW LAUNCHES IN U.S., SOUTH AFRICA AND INDIA IN THIS YEAR

CIPLA: Q4 BUSINESS GREW 7% VS 9-10% EST

CIPLA: CO EXEC SAYS Q4 IS ALWAYS WEAK QUARTER FOR INDIA-- SEASONAL VARIATION IMPACTED INDIA-1 BUSINESS - ETNOW

AUROBINDO PHARMA: CO SAYS COMPLETION OF US FDA INSPECTION AT UNIT VII OF APITORIA PHARMA -- CO SAYS INSPECTION CLOSES WITH 1 OBSERVATION -- OBSERVATION IS OF PROCEDURAL IN NATURE

CIPLA: CO APPROVED DIVIDEND OF 13 RUPEES PER SHARE

CIPLA: Q4 EBITDA 13B RUPEES VS 11.7B (YOY); 14.1B EST -- Q4 EBITDA MARGIN 21.35% VS 20.44% (YOY); EST 22.5%

CIPLA: Q4 REVENUE 62B RUPEES VS 56.6B (YOY); 62.51B EST

CIPLA: Q4 CONS NET PROFIT 9.4B RUPEES VS 5.26B (YOY); 9.23B EST

DR. LAL PATH LABS: Q4 EBITDA 1.4B RUPEES VS 1.15B (YOY) -- Q4 EBITDA MARGIN 26.53% VS 23.54% (YOY)

DR. LAL PATH LABS: CO APPROVED DIVIDEND OF 6 RUPEES PER SHARE

DR. LAL PATH LABS: Q4 REVENUE 5.5B RUPEES VS 4.9B (YOY)

DR. LAL PATH LABS: Q4 CONS NET PROFIT 850M RUPEES VS 567M (YOY)

HESTER BIO: CO IS REPURPOSING AND TRANSITIONING THEIR BSL 3 FACILITY (WHICH WAS BUILT TO MANUFACTURE THE DRUG SUBSTANCE OF THE COVID-19 VACCINE), TOWARDS COMMERCIAL PRODUCTION OF VETERINARY VACCINES, THEREBY FURTHER ENHANCING OUR MANUFACTURING CAPACITY

HESTER BIOSCIENCES: Q4 EBITDA 158M RUPEES VS 117M (YOY) -- Q4 EBITDA MARGIN 19.9% VS 17.35% (YOY)

HESTER BIOSCIENCES: Q4 REVENUE 792M RUPEES VS 673M (YOY)

HESTER BIOSCIENCES: Q4 CONS NET PROFIT 49.5M RUPEES VS 45M (YOY)

STRIDES PHARMA: CO RECEIVES USFDA APPROVAL FOR SEVELAMER CARBONATE TABLETS -- IT HAS A MARKET SIZE OF US$ 181M IN U.S.

SOLARA ACTIVE PHARMA SCIENCES: CO APPROVED RIGHTS ISSUE PRICE AT 375 RUPEES PER RIGHTS EQUITY SHARE -- RIGHTS ISSUE SIZE FOR AN AMOUNT AGGREGATING TO 4.50 BLN RUPEES

HIKAL: CO SAYS ANTICIPATE FAVORABLE SHIFT IN MARKET DYNAMICS OVER MID TO LONG TERM

HIKAL: Q4 EBITDA 945M RUPEES VS 880M (YOY) -- Q4 EBITDA MARGIN 18.38% VS 16.36% (YOY)

HIKAL: Q4 REVENUE 5.1B RUPEES VS 5.4B (YOY)

HIKAL: Q4 CONS NET PROFIT 340M RUPEES VS 360M (YOY)

ALEMBIC PHARMA: CO EXEC SAYS THE OUTLOOK FOR THE US BUSINESS APPEARS BETTER

ALEMBIC PHARMA: CO APPROVED DIVIDEND OF RUPEES 11 PER SHARE

ALEMBIC PHARMA: Q4 EBITDA 2.59B RUPEES VS 2.12B (YOY) -- Q4 EBITDA MARGIN 17.07% VS 15.09% (YOY)

ALEMBIC PHARMA: Q4 REVENUE INCREASE OF 8.11% FROM PREVIOUS

ALEMBIC PHARMA: Q4 CONS NET PROFIT 1.8B RUPEES VS 1.53B (YOY)

ZYDUS LIFE: CO ANNOUNCES COMPLETION OF ENROLMENT FOR EPICS IIITM PHASE 2B/3 TRIAL EVALUATING SAROGLITAZAR MG IN TREATMENT OF PRIMARY BILIARY CHOLANGITIS

ZYDUS LIFE: CO RECEIVES FINAL APPROVAL FROM USFDA FOR DAPSONE GEL -- IT HAD ANNUAL SALES OF USD 35.8M IN THE UNITED STATES

MAX HEALTHCARE INSTITUTE LTD: RS. 161.22 CRORES NSE BLOCK TRADE; FOR ~ 2016912 SHARES, AT RS. 799.35

APOLLO HOSPITALS ENTERPRISE LTD: Rs. 34.02 Crores NSE Block Trade; for ~ 58096 Shares, at Rs. 5856.15

DR REDDYS LABORATORIES: BARCLAYS RAISES TARGET PRICE TO $81 FROM $80

VIJAYA DIAGNOSTIC CENTRE: CO RECOMMENDS DIVIDEND OF 1 RUPEE PER EQUITY SHARE

VIJAYA DIAGNOSTIC CENTRE: Q4 EBITDA 631.1M RUPEES VS 491M (YOY) -- Q4 EBITDA MARGIN 40.66% VS 40.59% (YOY)

VIJAYA DIAGNOSTIC CENTRE: Q4 CONS NET PROFIT 334.5M RUPEES VS 275M (YOY); 258.5M (QOQ) -- Q4 REVENUE 1.55B RUPEES VS 1.21B (YOY); 1.33B (QOQ)

CIPLA: CO HAS RECEIVED 1 INSPECTIONAL OBSERVATION IN FORM 483

MANKIND PHARMA: BOARD MEETING ON MAY 15 TO CONSIDER Q4 RESULTS, RECOMMEND FINAL DIVIDEND; IF ANY & CONSIDER RAISING FUNDS

DR. REDDYS: CO AIMS TO BE A TOP FIVE ENTITY IN INDIA BY FY2030, TARGETING REVENUES AROUND INR 12,000 CRORES

DR. REDDYS: CO SAYS OVER 20 NEW PRODUCTS ARE SLATED FOR RELEASE IN THE U.S. MARKET IN THE COMING YEAR

DR. REDDYS: CO IS NOT PROVIDING SPECIFIC GUIDANCE FOR UPCOMING QUARTERS OR PRODUCT LINES, BUT REITERATED ITS LONG-TERM TARGET OF 25% EBITDA AND 25% ROCE, WITH DOUBLE-DIGIT GROWTH -- GUIDANCE FOR THE QUARTER IS 8.5% TO 9% - EARNINGS CONCALL

AMI ORGANICS: CO SAYS PATENT GRANTED FOR INVENTIONS TITLED “A PROCESS FOR ITS PREPARATION OF LUMATEPERONE TOSYLATE INTERMEDIATE” -- PATENT GRANTED FOR A TERM OF 20 YEARS

IPCA LABORATORIES: BOARD MEETING ON MAY 29 TO CONSIDER Q4 RESULTS -- CO TO RECOMMEND FINAL DIVIDEND FOR THE FINANCIAL YEAR 2023-24

DR REDDYS LABORATORIES: CO SAYS PARAG AGARWAL WILL RETIRE AS CHIEF FINANCIAL OFFICER -- CO SAYS M V NARASIMHAM, CURRENTLY DY. CHIEF FINANCIAL OFFICER ELEVATED TO CFO

DR. REDDY’S LAB: CO RECOMMENDED A FINAL DIVIDEND OF 40 RUPEES PER EQUITY SHARE

DR.REDDYS LABORATORIES: Q4 EBITDA 18.3B RUPEES VS 15.3B (YOY); 20.56B EST -- Q4 EBITDA MARGIN 25.74% VS 24.29% (YOY); 28% EST

DR.REDDYS LABORATORIES: Q4 CONS NET PROFIT 13.1B RUPEES VS 9.6B (YOY); 13.24B EST -- Q4 REVENUE 71.14B RUPEES VS 63.15B (YOY); 73.47B EST

GLAND PHARMA: CO RECEIVES APPROVAL FOR EDARAVONE INJECTION -- THE PRODUCT HAD US SALES OF APPROXIMATELY USD 19M

GLAND PHARMA: CO EXPECTS TO LAUNCH THIS PRODUCT THROUGH ITS MARKETING PARTNER WITHIN FY25

GLAND PHARMA: CO RECEIVES APPROVAL FROM THE UNITED STATES FOOD AND DRUG ADMINISTRATION (US FDA) FOR PLERIXAFOR INJECTION -- THE PRODUCT HAD US SALES OF APPROXIMATELY USD 152M

AARTI DRUGS: CO IS TARGETING INR 300 CRORE TO INR 350 CRORE OF ADDITIONAL REVENUE FROM THE ONCOLOGY SEGMENT OVER THE NEXT 24 TO 36 MONTHS

AARTI DRUGS: GUIDANCE FOR FY 25 IS FOR 10% TOP-LINE GROWTH DESPITE NEGATIVE RATE VARIANCE OF 5% TO 8% -- EBITDA MARGIN IS EXPECTED TO CROSS 14% MARK AND REACH 15% OVER THE NEXT THREE YEARS -- GROSS MARGINS ARE EXPECTED TO IMPROVE BY 1% TO REACH 35%

AARTI DRUGS: CO HAS PROVIDED GUIDANCE FOR THE NEAR FUTURE, PROJECTING A POSITIVE SHIFT IN THE EXPORT LANDSCAPE DUE TO INTEREST RATE REDUCTIONS, LOW STOCK LEVELS, AND AN UPSWING IN DEMAND

SUVEN LIFE SCIENCES: Q4 SL NET LOSS 31.2M RUPEES VS LOSS 22.5M (YOY); LOSS 47.7M (QOQ) -- Q4 REVENUE 23.9M RUPEES VS 26.1M (YOY); 24.5M (QOQ)

LUPIN: CO RECOMMENDED A DIVIDEND OF 8 RUPEES PER EQUITY SHARE

LUPIN: Q4 EBITDA 9.97B RUPEES VS 5.78B (YOY); 9.78B EST -- Q4 EBITDA MARGIN 20.09% VS 13.04% (YOY); 19.3% EST

LUPIN: Q4 CONS NET PROFIT 3.59B RUPEES VS 2.36B (YOY); 5B EST -- Q4 REVENUE 49.6B RUPEES VS 44.3B (YOY); 50.58B EST

BAJAJ HEALTHCARE: CO APPOINTS DAYASHANKAR PATEL AS CFO

LUPIN: TRAVOPROST OPHTHALMIC SOLUTION USP, 0.004% (RLD TRAVATAN Z®), HAD ESTIMATED ANNUAL SALES OF USD 77 MILLION IN THE U.S. (IQVIA MAT MARCH 2024)

LUPIN: CO RECEIVES APPROVAL FROM U.S. FDA FOR TRAVOPROST OPHTHALMIC SOLUTION USP -- TRAVOPROST OPHTHALMIC SOLUTION USP, 0.004%, IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

AUROBINDO PHARMA: CO INFORMS ABOUT NCLT ORDER APPROVING THE SCHEME OF AMALGAMATION OF MVIYES PHARMA VENTURES PRIVATE LIMITED AND AURONEXT PHARMA PRIVATE LIMITED, WHOLLY OWNED SUBSIDIARIES OF THE CO

CAPLIN POINT LABS: CO HAS RECEIVED COLOMBIAS INVIMA APPROVAL FOR ITS SOFTGEL CAPSULES DIVISION AT PUDUCHERRY

GLAND PHARMA LTD: Rs. 16.92 Crores NSE Block Trade; for ~ 100270 Shares, at Rs. 1687.30

ZYDUS LIFE: COS UNIT IN US ACQUIRES WORLDWIDE PROPRIETARY RIGHTS TO ZOKINVY AT NET BASE PRICE OF USD 45M FROM US-BASED EIGER BIOPHARMACEUTICALS

ZYDUS LIFESCIENCES: CO SAYS ZOKINVY IS APPROVED FOR THE TREATMENT OF A COLLECTION OF ULTRA-RARE, FATAL, GENETIC PREMATURE AGING DISEASES

ZYDUS LIFESCIENCES: SENTYNL THERAPEUTICS ANNOUNCES GLOBAL ACQUISITION OF ZOKINVY (LONAFARNIB) FOR TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME FROM EIGER BIOPHARMACEUTICALS

SUN PHARMA: CO TO ACQUIRE VALSTAR S.A., INCLUDING ITS UNIT KEMIPHARM S.A., FOR UP TO USD 31M

AARTI DRUGS: Q4 EBITDA 858.1M RUPEES VS 935.4M (YOY) -- Q4 EBITDA MARGIN 13.84% VS 12.6% (YOY)

AARTI DRUGS: Q4 CONS NET PROFIT 473.7M RUPEES VS 561M (YOY); 367M (QOQ) -- Q4 REVENUE 6.2B RUPEES VS 7.42B (YOY); 6.06B (QOQ)

AUROBINDO PHARMA: CO. SAYS COMPLETION OF US FDA INSPECTION AT UNIT II OF EUGIA PHARMA SPECIALITIES -- CO. SAYS INSPECTION CLOSED WITH 7 OBSERVATIONS; OBSERVATIONS ARE PROCEDURAL IN NATURE

IOL CHEMICALS AND PHARMA: CO HAS RECEIVED CERTIFICATE OF GOOD MANUFACTURING PRACTICES (GMP) FROM BRAZILIAN HEALTH REGULATORY AGENCY (ANVISA) FOR ALL THE 10 APIS MANUFACTURING UNITS SITUATED AT BARNALA, PUNJAB

DR. REDDYS LABORATORIES: CO ANNOUNCES THE LAUNCH OF DOXYCYCLINE CAPSULES, 40 MG* IN THE U.S.

HEALTHCARE GLOBAL: BAIN CAPITAL, TPG CAPITAL, MULTIPLES & BURJEEL ARE THE FINAL BIDDERS - CNBC TV 18

HEALTHCARE GLOBAL: BIDS BY THE 4 SHORT LISTED SUITORS ARE BETWEEN RUPEES 5700-5900CR EQUITY VALUE - CNBCTV 18

HEALTHCARE GLOBAL: PROMOTER CVC SHORTLISTS 4 BIDDERS FOR FINAL ROUND OF DEAL PROCESS - CNBCTV18

BLISS GVS PHARMA: CO HAS EXCEPTIONAL ITEM OF LOSS 292M RUPEES

BLISS GVS PHARMA: CO RECOMMEND FINAL DIVIDEND OF 0.50 RUPEES PER EQUITY SHARE

BLISS GVS PHARMA: Q4 EBITDA 283.5M RUPEES VS 62M (YOY) -- Q4 EBITDA MARGIN 14.31% VS 3.38% (YOY)

BLISS GVS PHARMA: Q4 CONS NET LOSS 91.5M RUPEES VS PROFIT 33M (YOY); PROFIT 276.1M (QOQ) -- Q4 REVENUE 1.98B RUPEES VS 1.85B (YOY); 2B (QOQ)

PROCTER & GAMBLE HEALTH: Q4 EBITDA 674.4M RUPEES VS 797M (YOY) -- Q4 EBITDA MARGIN 26.71% VS 24.82% (YOY)

PROCTER & GAMBLE HEALTH: Q4 SL NET PROFIT 465.6M RUPEES VS 592M (YOY); 721M (QOQ) -- Q4 REVENUE 2.52B RUPEES VS 3.21B (YOY); 3.1B (QOQ)

ZYDUS LIFESCIENCES: CO TO SELL ABOUT 25% STAKE IN JV BAYER ZYDUS PHARMA TO BAYER PHARMACEUTICALS FOR 2.82 BLN RUPEES

JUBILANT PHARMOVA: CO. APPOINTS MR. HARSHER SINGH AS CEO OF RADIOPHARMA BUSINESS

AJANTA PHARMA: Q4 EBITDA 2.78B RUPEES VS 1.49B (YOY) -- Q4 EBITDA MARGIN 26.40% VS 16.94% (YOY)

AJANTA PHARMA: Q4 REVENUE 10.54B RUPEES VS 8.82B (YOY)

AJANTA PHARMA: Q4 CONS NET PROFIT 2B RUPEES VS 1.2B (YOY)

AJANTA PHARMA: CO APPROVED SHARE BUYBACK AT THE PRICE OF 2770 RUPEES PER SHARE VIA TENDER OFFER ROUTE

AUROBINDO PHARMA: CO ENTERED INTO AGREEMENT WITH PURPLE BELLFLOWER PTY, SOUTH AFRICA

RPG LIFE SCIENCES: CO HAS RECOMMENDED A FINAL DIVIDEND OF 16 RUPEES PER EQUITY SHARE

RPG LIFE SCIENCES: Q4 EBITDA 207.2M RUPEES VS 159M (YOY) -- Q4 EBITDA MARGIN 16.32% VS 13.43% (YOY)

RPG LIFE SCIENCES: Q4 SL NET PROFIT 132.4M RUPEES VS 103.5M (YOY); 265M (QOQ) -- Q4 REVENUE 1.27B RUPEES VS 1.18B (YOY); 1.54B (QOQ)

METROPOLIS HEALTHCARE: CO SAYS SUIT FILED BY METROPOLIS BRAMSER LAB SERVICES BEFORE SUPREME COURT OF MAURITIUS DISMISSED

GRANULES INDIA: CO ANNOUNCED ANDA APPROVAL FOR COLCHICINE CAPSULES -- THESE CAPSULES HAS US SALES OF USD 55M

GLAND PHARMA: CO APPOINTED MR. SATNAM SINGH AS COO -- HE HAD WORKED WITH AUROBINDO PHARMA, SUN PHARMA & RANBAXY LAB

APOLLO HOSPITALS: APOLLO HEALTH RAISES MARGIN GUIDANCE TO 10-11% FROM 6-7%

GLAND PHARMA: CO RECEIVES USFDA APPROVAL FOR CETRORELIX ACETATE FOR INJECTION -- CETRORELIX ACETATE HAS US SALES OF 129M USD

GLENMARK PHARMA: CO RECEIVES ANDA APPROVAL FOR ACETAMINOPHEN AND IBUPROFEN TABLETS -- CO SAYS THESE TABLETS ACHIEVED ANNUAL SALES OF APPROXIMATELY USD 84.1 MILLION

CIPLA: CO UNIT CIPLA HEALTH COMPLETES PURCHASE OF COSMETICS & PERSONAL CARE BUSINESS FROM IVIA BEAUTE

AMI ORGANICS: CO APPROVED RAISING OF FUNDS WORTH UPTO 991M RUPEES VIA ISSUANCE OF SHARES ON PRIVATE PLACEMENT BASIS

APOLLO HOSPITALS ENTERPRISE: AHEL WOULD CONTINUE TO REMAIN LARGEST CONTROLLING SHAREHOLDER WITH AT LEAST 59.2% STAKE -- MERGER WITH KEIMED IS ESTIMATED TO BE EPS ACCRETIVE FROM YEAR 1

APOLLO HOSPITALS ENTERPRISE: ADVENT SHALL INVEST IN COMPULSORY CONVERTIBLE INSTRUMENTS OVER 2 TRANCHES TO SECURE 12.1% STAKE IN MERGED ENTITY -- ADVENT VALUING COMBINED ENTITY AT AN ENTERPRISE VALUE OF 224.81B RUPEES; KEIMED SHAREHOLDERS WOULD HOLD A MAXIMUM OF 25.7% STAKE IN COMBINED ENTITY

APOLLO HOSPITALS ENTERPRISE: CO SAYS APPROVAL FOR PRIMARY INVESTMENT OF 24.75B RUPEES BY RASMELI INTO APOLLO HEALTHCO -- APOLLO 2417 TO RAISE 24.75B RUPEES FROM ADVENT INTERNATIONAL; TO MERGE KEIMED WITH APOLLO 2417

AJANTA PHARMA: CO TO CONSIDER BUYBACK OF SHARES ON MAY 2ND

ZYDUS LIFE: CO RECEIVES FINAL APPROVAL FROM USFDA FOR TRETINOIN CREAM USP -- TRETINOIN CREAM USP, 0.1% HAD ANNUAL SALES OF USD 54.8 MN IN U.S.

DR REDDYS LABORATORIES LTD: Rs. 15.64 Crores NSE Block Trade; for ~ 25044 Shares, at Rs. 6246.80

LAURUS LABS LTD: Rs. 43.30 Crores NSE Block Trade; for ~ 1025901 Shares, at Rs. 422.10

LAURUS LABS LTD: Rs. 20.11 Crores NSE Block Trade; for ~ 479742 Shares, at Rs. 419.15

GLAXOSMITHKLINE PHARMA: GLAXOSMITHKLINE SUES PFIZER AND BIONTECH OVER MRNA TECHNOLOGY PATENTS IN COVID-19 VACCINES - US COURT FILING

ASTER DM HEALTHCARE: CO SAYS AMITABH JOHRI WILL BE RELIEVED FROM SERVICES OF JOINT CFO -- CO SAYS SUNIL KUMAR M R, CURRENTLY JOINT CFO, WILL ASSUME ROLE OF CFO

BIOCON: CO SAYS SCHEME OF AMALGAMATION OF BIOFUSION THERAPEUTICS WITH BIOCON PHARMA APPROVED BY INDIAN TRIBUNAL

LUPIN: CO RECEIVES APPROVAL FROM U.S. FDA FOR LOTEPREDNOL ETABONATE OPHTHALMIC SUSPENSION, 0.5% -- LOTEPREDNOL ETABONATE OPHTHALMIC SUSPENSION, 0.5% (RLD LOTEMAX®), HAD ESTIMATED ANNUAL SALES OF USD 59 MILLION IN THE U.S. (IQVIA MAT FEBRUARY 2024)

LAURUS LABS: CO FIXES MAY 8 AS RECORD DATE FOR PURPOSE OF DIVIDEND

LAURUS LABS: CO CAPITALIZES ON PLATFORM STRENGTHS TO SECURE LUCRATIVE CONTRACTS IN LATE-PHASE NCE PROJECTS AMID FAVORABLE INDUSTRY LANDSCAPE

LAURUS LABS: CO SAYS GROWTH PROJECTS RAMP-UP & NEW ASSETS COMING ONLINE

LAURUS LABS: CO SAYS GROWTH PROJECTS RAMP-UP & NEW ASSETS COMING ONLINE

LAURUS LABS: CO SAYS PRIORITIZING CAPEX INTO HIGH VALUE AND GROWING MARKET SEGMENTS

LAURUS LABS: CO SAYS EBITDA MARGINS IMPROVEMENT, SUPPORTED BY BETTER ASSET UTILIZATION & PRODUCTIVITY GAINS WHILE CONTINUING NEW INITIATIVES

LAURUS LABS : Q4 REVENUE 14.4B RUPEES VS 13.8B (YOY)

LAURUS LABS: Q4 EBITDA 2.41B RUPEES VS 2.85B (YOY) -- Q4 EBITDA MARGIN 16.77% VS 20.68% (YOY)

LAURUS LABS : Q4 CONS NET PROFIT AFTER TAX 753M RUPEES VS 1.07B (YOY)

GLENMARK LIFESCIENCE: CO SAYS 18 KL PHARMA CAPACITY IN DAHEJ IS UNDER VALIDATION AND WILL BE OPERATIONAL IN Q1 FY25

GLENMARK LIFESCIENCE: CO UPDATED REGARDING ANKLESHWAR SITE SAYS COMPLETION OF 208 KL INTERMEDIATE BLOCK CONSTRUCTION SIGNALS OPERATIONAL EXPANSION BY Q1 FY25

GLENMARK LIFESCIENCE: CO EXPANDS HP API PORTFOLIO WITH 6 NEW PRODUCTS -- HP API PORTFOLIO NOW EXTENDS TO 17 PRODUCTS WITH AN ADDRESSABLE MARKET OF USD 37B

GLENMARK LIFE SCIENCES: Q4 REVENUE 5.36B RUPEES VS 6.2B (YOY)

GLENMARK LIFE SCIENCE: Q4 EBITDA 1.41B RUPEES VS 2.1B (YOY) -- Q4 EBITDA MARGIN 26.36% VS 33.22% (YOY)

GLENMARK LIFE SCIENCES: Q4 SL NET PROFIT 980M RUPEES VS 1.5B (YOY)

DR. REDDY LABS: NESTLE INDIA AND CO TO FORM JV TO TAKE HEALTH SCIENCE NUTRACEUTICAL PORTFOLIO TO CONSUMERS ACROSS INDIA AND OTHER AGREED TERRITORIES

ASTRAZENECA: COS FOREIGN PARENT CO - ASTRAZENECA Q1 24 EARNINGS: CORE EPS $2.06 (EST $1.89) -- REVENUE: $12.68B (EST $11.82B) -- REITERATES TOTAL REV AND CORE EPS GUIDANCE -- IMFINZI REV $1.11B (EST $1.13B)

DIVI’S LAB: CO PLANS RUPEES 650-700 CRORE CAPACITY ADDITION, EYES OPERATIONAL EXPANSION BY 2027

JUBILANT PHARMOVA: CO ANNOUNCES COMPLETION OF USFDA AUDIT OF RADIOPHARMACEUTICALS MANUFACTURING FACILITY AT MONTREAL, CANADA -- CO SAYS USFDA HAS ISSUED 5 OBSERVATIONS PURSUANT TO THE COMPLETION OF AUDIT

SYNGENE INTERNATIONAL: CO RECOMMENDED A FINAL DIVIDEND OF 1.25 RUPEES PER EQUITY SHARE

SYNGENE INTERNATIONAL: Q4 EBITDA 3.17B RUPEES VS 3.14B (YOY) -- Q4 EBITDA MARGIN 34.56% VS 31.59% (YOY)

SYNGENE INTERNATIONAL: Q4 CONS NET PROFIT 1.89B RUPEES VS 1.79B (YOY); 1.12B (QOQ) -- Q4 REVENUE 9.17B RUPEES VS 9.94B (YOY); 8.54B (QOQ)

ZYDUS LIFESCIENCES: CO SAYS USFDA INSPECTION CLOSED WITH 10 OBSERVATIONS AT JAROD, NEAR VADODARA

LUPIN: CO RECEIVES EIR FROM U.S. FDA FOR ITS AURANGABAD MANUFACTURING FACILITY -- INSPECTION WAS CONDUCTED FROM MARCH 6 TO MARCH 15, 2024 -- U.S. FDA HAS DETERMINED THAT THE INSPECTION CLASSIFICATION OF THE FACILITY IS VOLUNTARY ACTION INDICATED (VAI)

DR REDDYS LABORATORIES: CO SAYS ISSUE WAS DISCOVERED DURING AN ACCELERATED STABILITY TEST IN ADDITION TO CUSTOMER COMPLAINTS -- CO SAYS IT IS VOLUNTARILY RECALLING SIX (6) LOTS OF SAPROPTERIN DIHYDROCHLORIDE POWDER

DR REDDYS LABORATORIES: CO ISSUES VOLUNTARY NATIONWIDE RECALL OF SAPROPTERIN DIHYDROCHLORIDE POWDER FOR ORAL SOLUTION 100 MG DUE TO SUB-POTENCY

AMI ORGANICS: BOARD MEETING ON APRIL 26 TO CONSIDER PROPOSAL TO RAISE FUNDS

NATCO PHARMA: CO IS IN RECEIPT OF THE EIR FROM USFDA, CONCLUDING THE INSPECTION AS CLOSED

ZYDUS LIFESCIENCES: COS NEW DRUG APPLICATION OF ZYDUS INNOVATIVE DRUG DESIDUSTAT TABLETS BY CHINA MEDICAL SYSTEM HOLDINGS LTD ACCEPTED IN CHINA

AARTI DRUGS: CO HAS RECEIVED 5 INSPECTIONAL OBSERVATIONS IN FORM 483 FOR BADDI FACILITY

FORTIS HEALTHCARE LTD: Rs. 35.91 Crores NSE Block Trade; for ~ 807370 Shares, at Rs. 444.80

LUPIN: CO TO CONSIDER Q4 RESULTS ON MAY 6

ZYDUS LIFESCIENCES: CO LAUNCHES MIRABEGRON EXTENDED-RELEASE TABLETS IN THE US -- TABLETS USP 25MG AND 50MG HAD ANNUAL SALES OF USD 2.42B IN THE US

BIOCON: CO RECEIVED APPROVAL FROM THE SOUTH AFRICAN HEALTH PRODUCTS REGULATORY AUTHORITY (SAHPRA) FOR VERTICALLY INTEGRATED, COMPLEX DRUG PRODUCT TACROLIMUS CAPSULE 0.5MG, 1MG AND 5MG STRENGTHS, IN SOUTH AFRICA -- THIS IS THE CO’S FIRST APPROVAL IN THIS COUNTRY

LAURUS LABS: CO SAYS USFDA TODAY COMPLETED INSPECTION OF OUR API MANUFACTURING FACILITIES UNIT–1 AND UNIT–3, PARAWADA, ANAKAPALLI (VISAKHAPATNAM), ANDHRA PRADESH -- INSPECTION WAS CONDUCTED FROM 15TH APRIL, 2024 TO 19TH APRIL, 2024 -- INSPECTION WAS SUCCESSFULLY CLOSED WITHOUT ANY 483 OBSERVATIONS

STRIDES PHARMA: INVESTOR MUKUL MAHAVIR AGRAWAL ADDED 0.1% STAKE IN CO DURING Q4

METROPOLIS HEALTHCARE: CO SAYS NCLT HAS APPROVED THE DISSOLUTION OF CO UNIT DR.GANESANS HITECH DIAGNOSTIC CENTRE PVT LTD

LAURUS LABS: CO TO CONSIDER Q4 RESULTS ON APRIL 25

MARKSANS PHARMA: CO SAYS AFTER CONCLUSION OF THE USFDA INSPECTION AT GOA FACILITY, CO HAS RECEIVED 5 INSPECTIONAL OBSERVATIONS IN FORM 483

IPCA LABS: Rs 27.37cr NSE Block Trade; for ~204544 shares, at Rs 1337.95

APOLLO HOSPITALS: CO EXEC SAYS DISCUSSION ON STANDARD RATES LIKELY TO TAKE PLACE POST ELECTIONS - CNBC TV18

SHILPA MEDICARE: CO LAUNCHES PEMETREXED INJECTION -- INJECTION HAS US SALES OF 287M USD

NATCO PHARMA: CO SAYS COMPLAINT AGAINST CO RELATING TO MARKETING OF DASH PHARMACEUTICALS DIAZEPAM INJECTION PREFILLED SYRINGE IN UNITED STATES

NATCO PHARMA: CO SAYS FRESENIUS KABI USA, LLC AND FRESENIUS KABI DEUTSCHLAND GMBH HAVE FILED A COMPLAINT AGAINST NATCO PHARMA USA LLC

PIRAMAL PHARMA: CO SAYS US FDA HAS ISSUED AN ESTABLISHMENT INSPECTION REPORT (EIR) FOR THE MANUFACTURING FACILITY LOCATED IN RIVERVIEW, USA AND THE INSPECTION HAS NOW BEEN SUCCESSFULLY CLOSED BY THE US FDA

BIOCON: CO SIGNS EXCLUSIVE LICENSING AND SUPPLY AGREEMENT FOR GENERIC OZEMPIC (SEMAGLUTIDE) COMMERCIALIZATION IN BRAZIL WITH BIOMM S.A., WHICH IS USED TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE-2 DIABETES

JUBILANT PHARMOVA: FACILITY IS CONSIDERED TO BE IN ACCEPTABLE STATE OF COMPLIANCE WITH REGARD TO CURRENT GOOD MANUFACTURING PRACTICES

JUBILANT PHARMOVA: CO UNIT RECEIVED A COMMUNICATION FROM THE USFDA THROUGH WHICH THE REGULATORY AGENCY INTIMATED THAT PURSUANT TO ITS JAN 25 TO FEB 2, 2024 AUDIT OF JGL’S SOLID DOSAGE MANUFACTURING FACILITY AT ROORKEE, IT HAS DETERMINED THE INSPECTION CLASSIFICATION OF THE FACILITY AS “VOLUNTARY ACTION INDICATED (VAI)"

ZYDUS LIFESCIENCES: CO UNIT SENTYNL THERAPEUTICS RECEIVES MHRA AUTHORIZATION OF NULIBRY® (FOSDENOPTERIN) FOR TREATMENT OF MOCD TYPE A IN GREAT BRITAIN - RTRS

SHILPA MEDICARE: CO SAYS EUROPE GMP APPROVAL OF SHILPA MEDICARE UNIT 4, JADCHERLA, TELANGANA -- UNIT 4, JADCHERLA; TELANGANA, INDIA INSPECTED BY AGES, AUSTRIA FROM 22 JAN UNTIL 26 JAN -- CO SAYS FOLLOWING SUCCESSFUL INSPECTION, UNIT ISSUED GMP CERTIFICATION FROM AGES, AUSTRIA

SMS PHARMA: CO PROMOTER GROUP INCREASE THEIR STAKE BY 0.35% IN CO DURING Q4

MAX HEALTHCARE: CO TO INVEST RS 5,000 CR ON DOUBLING BED CAPACITY IN 4-5 YEARS - PTI

FORTIS HEALTH: INVESTOR REKHA JHUNJHUNWALA REDUCE STAKE BY 0.59% IN CO DURING Q4

AUROBINDO PHARMA: Rs 21.95cr NSE Block Trade; for ~200767 shares, at Rs 1093.5

CAPLIN POINT: CAPLIN STERILES GETS USFDA APPROVAL FOR OFLOXACIN OPHTHALMIC SOLUTION -- IT HAS US SALES OF USD 52M

FORTIS HEALTH: Rs 44.14cr NSE Block Trade; for ~1011053 shares, at Rs 436.55

CIPLA: DEAL VALUE INCLUDES 1.1B RUPEES IF CERTAIN FINANCIAL PARAMETERS ARE MET FOR NEXT 3 YEARS -- TARGET CONSUMER BASE SEEKS VARIETY, ESPECIALLY WHEN IT COMES TO NEW BRANDS IN PERSONAL CARE

CIPLA: CO SAYS ACQUISITION OF A BUSINESS UNDERTAKING FROM IVIA BEAUTE PVT LTD, INDIA -- COST OF ACQUISITION 1.3B RUPEES ON CLOSING DATE

MARKSANS PHARMA: Rs 34.84cr NSE Block Trade; for ~2209214 shares, at Rs 157.7

AUROBINDO PHARMA: Rs 21.76cr NSE Block Trade; for ~201824 shares, at Rs 1078

HIKAL: CO APPOINTS DR. K. SURESH BABU AS HEAD - QUALITY OF THE CO -- DR. K. SURESH BABU PREVIOUSLY WORKED AT PIRAMAL PHARMA, SUN PHARMA AND MOST RECENTLY WITH NATCO PHARMA

SUVEN LIFE SCIENCES: CO TO PRESENT PHASE-2 POSITIVE RESULTS ON SAMELISANT (SUVN-G3031) AT AMERICAN ACADEMY OF NEUROLOGY (AAN) 2024 ANNUAL MEETING, DENVER, USA

AUROBINDO PHARMA: Rs 53.66cr NSE Block Trade; for ~496187 shares, at Rs 1081.35

GRANULES INDIA: CO SAYS US FDA AUDIT FOR GRANULES INDIA’S UNIT V FACILITY RESULTS IN ZERO 483

ASTER DM HEALTHCARE: CO DECLARED SPECIAL DIVIDEND OF 118 RUPEES PER SHARE -- CO SAYS DECIDED NOT TO DECLARE AN INTERIM DIVIDEND FOR FINANCIAL YEAR 2023-24

AMI ORGANICS: CO APPROVES RAISING UP TO 5B RUPEES VIA QIP

LUPIN: CO SAYS USFDA INSPECTION WAS CONDUCTED FROM APRIL 8 TO APRIL 12, 2024 OF COS DABHASA FACILITY AND CONCLUDED WITH NO OBSERVATIONS

JB CHEMICALS: Rs 18.03cr NSE Block Trade; for ~100808 shares, at Rs 1788.9

DR REDDYS LAB: CO SAYS NERIVIO TO BE LAUNCHED IN SOUTH AFRICA LATER THIS MONTH, AND SUBSEQUENTLY IN SPAIN AND UK -- CO SAYS NERIVIO® EXPERIENCE HAS SO FAR BENEFITED OVER 45,000 PATIENTS GLOBALLY

DR. REDDY’S LAB: CO LAUNCHES DRUG-FREE MIGRAINE MANAGEMENT DEVICE NERIVIO® IN EUROPE FOLLOWING SUCCESSFUL LAUNCH IN INDIA -- CO HAS LAUNCHED NERIVIO® IN GERMANY THROUGH ITS STEP-DOWN SUBSIDIARY BETAPHARM

PIRAMAL PHARMA: CO FORAYS INTO MENS GROOMING MARKET WITH THE LAUNCH OF BOHEM

BIOCON: Rs 42.82cr NSE Block Trade; for ~1524317 shares, at Rs 280.9

GLENMARK PHARMA: Rs 33.34cr NSE Block Trade; for ~318598 shares, at Rs 1046.4

METROPOLIS HEALTHCARE: Rs 15.21cr NSE Block Trade; for ~85200 shares, at Rs 1785.65

ALKEM: NOMURA SAYS HIGH CHANCE OF OAI FOR BADDI UNIT 10 OBSERVATONS IN FORM 483 BADDI CONTRIBUTED 8-10% OF CONSOLIDATED SALES PLANNED LAUNCHES FROM BADDI WILL BE DELAYED ON OAI CLASSIFICATION

SPARC: CO HAS DECIDED TO CLOSE THE ONGOING PROSEEK STUDY

SPARC: CO SAYS BOTH LOW DOSE AND HIGH DOSE VODOBATINIB ARMS DID NOT MEET THE PRE-SPECIFIED PRIMARY ENDPOINT OF CHANGE IN MDS-UPDRS PART III TOTAL SCORE AT WEEK 40 COMPARED TO PLACEBO

SPARC: CO SAYS INTERIM ANALYSIS WAS PERFORMED FOR 442 PATIENTS WHO COMPLETED PART I OF THE PROSEEK STUDY

SPARC: CO ANNOUNCES RESULTS FROM THE PLANNED INTERIM ANALYSIS OF THE PROSEEK STUDY OF VODOBATINIB IN PATIENTS WITH EARLY PARKINSON’S DISEASE

LUPIN: DOXYCYCLINE CAPSULES, 40 MG IS INDICATED FOR THE TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA IN ADULT PATIENTS

LUPIN: CO LAUNCHES FIRST GENERIC VERSION OF ORACEA® (DOXYCYCLINE CAPSULES) IN THE UNITED STATES -- DOXYCYCLINE CAPSULES HAD ESTIMATED ANNUAL SALES OF USD 128M IN THE U.S. (IQVIA MAT FEBRUARY 2024)

JB CHEMICALS: Rs 40.77cr NSE Block Trade; for ~237093 shares, at Rs 1719.75

NATCO PHARMA: CO SAYS WARNING LETTER MAY CAUSE DELAY / WITHHOLDING OF PENDING PRODUCT APPROVALS FROM THIS SITE

NATCO PHARMA: CO HAS RECEIVED A WARNING LETER DATED 8TH APRIL, 2024 FROM USFDA -- CO WILL RESPOND TO THE WARNING LETER WITHIN THE STIPULATED TIMEMELINES AND WORK CLOSELY WITH THE USFDA TO ADDRESS THE CONCERNS

STRIDES PHARMA: CO HAS SET A TARGET TO LAUNCH 60 NEW PRODUCTS OVER 3 YEARS IN THE US

STRIDES PHARMA: CO FURTHER SAYS CO HAS 260 CUMULATIVE ANDA FILINGS (INCLUDING THE RECENTLY ACQUIRED PORTFOLIO FROM ENDO AT CHESTNUT RIDGE) WITH USFDA, OF WHICH 245 ANDAS HAVE BEEN APPROVED

STRIDES PHARMA: CO RECEIVES USFDA APPROVAL FOR FLUOXETINE TABS -- FLUOXETINE TABLETS HAS A MARKET SIZE OF USD 23.9M AS PER IMS

(CORRECTION) GLAND PHARMA: NICOMAC MACHINERY LIKELY TO SELL UP TO 4.4% EQUITY IN GLAND PHARMA, FLOOR PRICE AT RS 1,725/SHARE -- OFFER SIZE OF THE BLOCK LIKELY AT UP TO RS 1,400 CRORE -- FLOOR PRICE IS AT DISCOUNT OF 7.3% TO CMP - CNBCTV18, CITING SOURCES

GLENMARK PHARMA: NICOMAC MACHINERY LIKELY TO SELL UP TO 4.4% EQUITY IN GLENMARK PHARMA, FLOOR PRICE AT RS 1,725/SHARE -- OFFER SIZE OF THE BLOCK LIKELY AT UP TO RS 1,400 CRORE -- FLOOR PRICE IS AT DISCOUNT OF 7.3% TO CMP - CNBCTV18, CITING SOURCES

AMI ORGANICS: BOARD MEETING ON APRIL 12 TO CONSIDER RAISING FUNDS

SHILPA MEDICARE: CO SAYS BOARD APPROVES OPENING OF THE QIP, FLOOR PRICE AT 477.33 RUPEES PER SHARE

ASTRAZENECA: ASTRAZENECA AND DAIICHI SANKYO’S ENHERTU HAS BECOME THE FIRST DRUG OF ITS KIND TO BE GRANTED APPROVAL TO TREAT TUMORS ANYWHERE IN THE BODY IF PATIENTS TEST POSITIVE FOR A PROTEIN KNOWN TO SPEED UP CANCER GROWTH: BLOOMBERG

DIVIS LABS: Rs 18.99cr NSE Block Trade; for ~49869 shares, at Rs 3808.2

CIPLA: Rs 25.15cr NSE Block Trade; for ~171315 shares, at Rs 1467.95

FORTIS HEALTHCARE: Rs 44.72cr NSE Block Trade; for ~1014375 shares, at Rs 440.85

ASTER DM HEALTHCARE: BOARD MEETING ON APRIL 12 TO CONSIDER DECLARATION OF INTERIM DIVIDEND FOR THE FINANCIAL YEAR 2023-24 -- CO TO CONSIDER DECLARATION OF SPECIAL DIVIDEND ON ACCOUNT OF SEGREGATION OF GCC BUSINESS

SHALBY: CO APPROVED AVAILING OF RENEWED AND ENHANCED BANKING FACILITIES UPTO 1.69B RUPEES FROM INDUSIND BANK

DR REDDYS LABORATORIES: BAYER HAS GRANTED NON-EXCLUSIVE RIGHTS TO DR. REDDYS UNDER BRAND NAME GANTRA

DR REDDYS LABORATORIES: BAYER AND DR. REDDYS SIGN A MARKETING AND DISTRIBUTION AGREEMENT FOR SECOND BRAND OF VERICIGUAT IN INDIA -- REDDYS WILL MARKET DRUG UNDER A SECOND BRAND NAME GANTRA IN INDIA

AUROBINDO PHARMA: CO SAYS COMPLETION OF US FDA INSPECTION AT NEW INJECTABLE FACILITY OF EUGIA STERILES -- CO SAYS INSPECTION CLOSED WITH 3 OBSERVATIONS AT NEW INJECTABLE FACILITY OF EUGIA STERILES

LAURUS LABS: USFDA TAGS API UNT OF CO UNIT AS OFFICIAL ACTION INDICATED (OAI) - CNBC AAWAZ

FORTIS: CO ANNOUNCES QUASHING OF 124 CRORE TAX DEMAND

ARTEMIS MEDICARE SERVICES: CO APPROVED FUND RAISE WORTH UPTO 3.3B RUPEES

CIPLA: COS PATALGANGA FACILITY RECEIVES SIX OBSERVATIONS IN USFDA INSPECTION

IOL CHEMICALS AND PHARMA: CO SAYS EUROPEAN DIRECTORATE FOR THE QUALITY OF MEDICINES & HEALTH CARE (EDQM) HAS ISSUED A CERTIFICATE OF SUITABILITY FOR GABAPENTIN

SUN PHARMA: CO SAYS DHEERAJ SINHA APPOINTED AS CIO, EXEC VP

GUFIC BIOSCIENCES: CO INCORPORATES A WHOLLY-OWNED SUBSIDIARY ‘VEIRA LIFE FZE’ IN DUBAI, UAE

ASTER DM HEALTHCARE: CO TO FOCUS ON GREENFIELD AND BROWNFIELD EXPANSIONS IN NEXT 3 YEARS -- CO PLANS TO ADD 1700 BEDS BY FY27 THROUGH ORGANIC ROUTE

ASTER DM HEALTHCARE: CO CONCLUDES SEPARATION OF INDIA AND GCC BUSINESSES

GLOBAL HEALTH: Rs 20.17cr NSE Block Trade; for ~150203 shares, at Rs 1343.1

GRANULES: CO FOREIGN SUBSIDIARY HAS RECEIVED A COMMUNICATION FROM THE US FDA INDICATING THE INSPECTION CLASSIFICATION AS “VOLUNTARY ACTION INDICATED

AUROBINDO PHARMA: Rs 17.9cr NSE Block Trade; for ~160535 shares, at Rs 1114.9

BIOCON: CO SAYS COMPLETED TRANSACTION OF TRANSFER OF BRANDED FORMULATIONS BUSINESS IN INDIA TO ERIS LIFESCIENCES

ARTEMIS MEDICARE SERVICES: BOARD MEETING ON APRIL 5 TO CONSIDER PROPOSAL FOR RAISING OF FUNDS

SYNGENE INTERNATIONAL: Rs 21.64cr NSE Block Trade; for ~302600 shares, at Rs 715.1

GLOBAL HEALTH: Rs 19.96cr NSE Block Trade; for ~150140 shares, at Rs 1329.2

RAINBOW CHILDRENS MEDICARE: Rs 49.49cr NSE Block Trade; for ~361899 shares, at Rs 1367.55

PIRAMAL PHARMA: DGTR INITIATES ANTI-DUMPING INVESTIGATION ON IMPORTS OF VITAMIN-A PALMITATE FROM CHINA PR, EU, AND SWITZERLAND

ZYDUS LIFESCIENCES: CO RECEIVES APPROVAL FOR THE NAME ‘USNOFLAST’ AS RECOMMENDED NAME FOR ZYIL1 FROM THE WHO INTERNATIONAL NON-PROPRIETARY NAMES (INN)

THYROCARE TECH: CO RECEIVED RECTIFICATION ORDER RAISING DEMAND AT 51.3 CR RUPEES

ALEMBIC PHARMA: CO HAS RECEIVED ONE USFDA PRODUCT APPROVAL (TENTATIVE) DURING THE QUARTER ENDED 31 ST MARCH, 2024

AUROBINDO PHARMA: CO UNIT CURATEQ BIOLOGICS IN AGREEMENT WITH MERCK SHARP & DOHME SINGAPORE TO EXTEND THE TIMELINES -- EXPANSION OF BIOLOGICS MANUFACTURING FACILITIES AND EXPLORING THE POSSIBILITIES TO ENTER INTO CONTRACT MANUFACTURING OPERATIONS

STRIDES PHARMA SCIENCE: CO SAYS CORPORATE INSOLVENCY RESOLUTION PROCESS AGAINST STRIDES ALATHUR STANDS STAYED BY APPELLATE TRIBUNAL

SOLARA ACTIVE PHARMA: CO ANNOUNCES SALE OF 100% SHAREHOLDING IN UNIT, SEQUENT PENEMS PVT. LTD., TO SYMBIO GENERRICS PVT. LTD. FOR 12.50 CR RUPEES